詳細検索

詳細検索

お問い合わせ

Immunoassay Market by Product, Technology, Specimen, Application, End User & Region  Global Forecast to 2031

Immunoassay Market by Product, Technology, Specimen, Application, End User & Region Global Forecast to 2031


The global immunoassay market is estimated to be valued at USD 31.65 billion in 2026 and is projected to reach USD 44.49 billion by 2031, registering a CAGR of 7.0% during the forecast period. Mar... もっと見る

 

 

出版社
MarketsandMarkets
マーケッツアンドマーケッツ
出版年月
2026年10月22日
電子版価格
US$4,950
シングルユーザーライセンス
ライセンス・価格情報/注文方法はこちら
納期
通常2営業日以内
ページ数
481
図表数
608
言語
英語

英語原文をAIを使って翻訳しています。


 

お問い合わせ

お問合せ種類/内容 *

補足が有ればご記入ください
貴社名*
ご担当者名 * 姓 名
メールアドレス *

ページTOPに戻る



図表リスト

FIGURE 1 IMMUNOASSAY MARKET SEGMENTATION & REGIONAL SCOPE 39.
FIGURE 2 IMMUNOASSAY MARKET: YEARS CONSIDERED 41.
FIGURE 3 KEY INSIGHTS & MARKET HIGHLIGHTS 43.
FIGURE 4 GLOBAL IMMUNOASSAY MARKET, 2024–2031 44.
FIGURE 5 MAJOR STRATEGIES ADOPTED BY KEY PLAYERS IN IMMUNOASSAY MARKET, 2024–2026 44.
FIGURE 6 DISRUPTIVE TRENDS IMPACTING GROWTH OF IMMUNOASSAY MARKET 45.
FIGURE 7 HIGH-GROWTH SEGMENTS & EMERGING FRONTIERS IN.
IMMUNOASSAY MARKET, 2025 46.
FIGURE 8 ASIA PACIFIC TO REGISTER HIGHEST GROWTH DURING FORECAST PERIOD 47.
FIGURE 9 HIGH PREVALENCE OF CHRONIC AND INFECTIOUS DISEASES TO DRIVE MARKET 48.
FIGURE 10 REAGENTS & KITS SEGMENT TO DOMINATE MARKET DURING FORECAST PERIOD 49.
FIGURE 11 CLIA SEGMENT TO LEAD MARKET DURING FORECAST PERIOD 49.
FIGURE 12 BLOOD SAMPLES SEGMENT TO LEAD MARKET DURING FORECAST PERIOD 50.
FIGURE 13 INFECTIOUS DISEASES SEGMENT TO LEAD MARKET DURING FORECAST PERIOD 50.
FIGURE 14 HOSPITALS & CLINICS SEGMENT TO COMMAND LARGEST.
SHARE DURING FORECAST PERIOD 51.
FIGURE 15 ASIA PACIFIC TO REGISTER HIGHEST GROWTH DURING FORECAST PERIOD 51.
FIGURE 16 IMMUNOASSAY MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES,.
AND CHALLENGES 53.
FIGURE 17 IMMUNOASSAY MARKET: PORTER’S FIVE FORCES ANALYSIS 71.
FIGURE 18 IMMUNOASSAY MARKET: SUPPLY CHAIN ANALYSIS 76.
FIGURE 19 IMMUNOASSAY MARKET: VALUE CHAIN ANALYSIS 77.
FIGURE 20 IMMUNOASSAY MARKET: ECOSYSTEM ANALYSIS 78.
FIGURE 21 IMMUNOASSAY MARKET: TRENDS/DISRUPTIONS IMPACTING.
CUSTOMERS’ BUSINESSES 85.
FIGURE 22 NUMBER OF DEALS & FUNDING ACTIVITIES IN IMMUNOASSAY MARKET 86.
FIGURE 23 TOP 10 PATENT OWNERS/APPLICANTS IN IMMUNOASSAY MARKET,.
JANUARY 2015–DECEMBER 2024 93.
FIGURE 24 MARKET POTENTIAL OF AI IN IMMUNOASSAY MARKET 96.
FIGURE 25 US: REGULATORY PROCESS FOR IN VITRO DIAGNOSTIC DEVICES 99.
FIGURE 26 CANADA: REGULATORY PROCESS FOR IN VITRO DIAGNOSTIC DEVICES 100.
FIGURE 27 JAPAN: REGULATORY PROCESS FOR IN VITRO DIAGNOSTIC DEVICES 102.
FIGURE 28 INDIA: REGULATORY PROCESS FOR IN VITRO DIAGNOSTIC DEVICES 104.
FIGURE 29 MEXICO: REGULATORY PROCESS FOR IN VITRO DIAGNOSTIC DEVICES 106.
FIGURE 30 BRAZIL: REGULATORY PROCESS FOR IN VITRO DIAGNOSTIC DEVICES 108.
FIGURE 31 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS, BY END USER 113.
FIGURE 32 KEY BUYING CRITERIA, BY END USER 114.
FIGURE 33 NORTH AMERICA: IMMUNOASSAY MARKET SNAPSHOT 248.
FIGURE 34 ASIA PACIFIC: IMMUNOASSAY MARKET SNAPSHOT 302.
FIGURE 35 REVENUE ANALYSIS OF KEY PLAYERS IN IMMUNOASSAY MARKET,.
2023–2025 (USD MILLION) 364.
FIGURE 36 IMMUNOASSAY MARKET SHARE ANALYSIS, 2025 (GLOBAL) 365.
FIGURE 37 IMMUNOASSAY MARKET: COMPANY EVALUATION MATRIX (KEY PLAYERS), 2025 367.
FIGURE 38 IMMUNOASSAY MARKET: COMPANY FOOTPRINT 368.
FIGURE 39 IMMUNOASSAY MARKET: COMPANY EVALUATION MATRIX.
(STARTUPS/SMES), 2025 373.
FIGURE 40 EV/EBITDA OF KEY VENDORS 376.
FIGURE 41 YEAR-TO-DATE (YTD) PRICE TOTAL RETURN AND 5-YEAR STOCK BETA.
OF KEY VENDORS 376.
FIGURE 42 IMMUNOASSAY MARKET: BRAND/PRODUCT COMPARISON 377.
FIGURE 43 ABBOTT: COMPANY SNAPSHOT (2025) 381.
FIGURE 44 F. HOFFMANN-LA ROCHE LTD.: COMPANY SNAPSHOT (2025) 387.
FIGURE 45 SIEMENS HEALTHINEERS AG: COMPANY SNAPSHOT (2025) 393.
FIGURE 46 DANAHER CORPORATION: COMPANY SNAPSHOT (2025) 398.
FIGURE 47 THERMO FISHER SCIENTIFIC INC.: COMPANY SNAPSHOT (2025) 405.
FIGURE 48 REVVITY INC.: COMPANY SNAPSHOT (2025) 410.
FIGURE 49 WATERS CORPORATION: COMPANY SNAPSHOT (2025) 413.
FIGURE 50 DIASORIN S.P.A.: COMPANY SNAPSHOT (2025) 416.
FIGURE 51 BIO-RAD LABORATORIES, INC.: COMPANY SNAPSHOT (2025) 421.
FIGURE 52 QUIDELORTHO CORPORATION: COMPANY SNAPSHOT (2025) 425.
FIGURE 53 BIOMÉRIEUX: COMPANY SNAPSHOT (2025) 430.
FIGURE 54 QIAGEN: COMPANY SNAPSHOT (2025) 434.
FIGURE 55 SYSMEX CORPORATION: COMPANY SNAPSHOT (2025) 437.
FIGURE 56 AGILENT TECHNOLOGIES, INC.: COMPANY SNAPSHOT (2025) 442.
FIGURE 57 SHENZHEN MINDRAY BIO-MEDICAL ELECTRONICS CO., LTD.:.
COMPANY SNAPSHOT (2025) 444.
FIGURE 58 IMMUNOASSAY MARKET: RESEARCH DESIGN 459.
FIGURE 59 IMMUNOASSAY MARKET: KEY DATA FROM SECONDARY SOURCES 461.
FIGURE 60 IMMUNOASSAY MARKET: KEY PRIMARY SOURCES 461.
FIGURE 61 IMMUNOASSAY MARKET: KEY INSIGHTS FROM INDUSTRY EXPERTS 464.
FIGURE 62 BREAKDOWN OF PRIMARY INTERVIEWS: SUPPLY- AND.
DEMAND-SIDE PARTICIPANTS 464.
FIGURE 63 BREAKDOWN OF PRIMARY INTERVIEWS: BY COMPANY TYPE,.
DESIGNATION, AND REGION 465.
FIGURE 64 IMMUNOASSAY MARKET: COMPANY REVENUE ESTIMATION.
(REVENUE SHARE ANALYSIS) 466.
FIGURE 65 IMMUNOASSAY MARKET: CAGR PROJECTIONS (SUPPLY-SIDE ANALYSIS) 467.
FIGURE 66 IMMUNOASSAY MARKET: TOP-DOWN APPROACH 468.
FIGURE 67 IMMUNOASSAY MARKET: DATA TRIANGULATION METHODOLOGY 469.
TABLE 1 IMMUNOASSAY MARKET: INCLUSIONS & EXCLUSIONS 40.
TABLE 2 INCREASING INCIDENCE OF CANCER, BY REGION, 2024 VS. 2040 (MILLION) 55.
TABLE 3 NUMBER OF NEW CANCER CASES, BY CANCER TYPE, 2024 55.
TABLE 4 DETECTION TIME OF DRUG OR DRUG CLASS IN URINE TESTING 56.
TABLE 5 NEW TESTS LAUNCHED BY KEY PLAYERS, 2023–2026 63.
TABLE 6 LAB-ON-CHIP IMMUNOASSAYS/DEVICES/SYSTEMS OFFERED BY KEY PLAYERS 63.
TABLE 7 IMMUNOASSAY MARKET: PORTER’S FIVE FORCES 71.
TABLE 8 GDP PERCENTAGE CHANGE (%), BY KEY COUNTRY, 2023–2030 73.
TABLE 9 NORTH AMERICA: MACROECONOMIC INDICATORS 74.
TABLE 10 EUROPE: MACROECONOMIC INDICATORS 74.
TABLE 11 ASIA PACIFIC: MACROECONOMIC INDICATORS 75.
TABLE 12 LATIN AMERICA: MACROECONOMIC INDICATORS 75.
TABLE 13 MIDDLE EAST & AFRICA: MACROECONOMIC INDICATORS 75.
TABLE 14 IMMUNOASSAY MARKET: ROLE OF COMPANIES IN ECOSYSTEM 79.
TABLE 15 AVERAGE SELLING PRICE TREND OF IMMUNOASSAY PRODUCTS,.
BY KEY PLAYER, 2024–2026 (USD) 80.
TABLE 16 AVERAGE SELLING PRICE TREND OF CLINICAL IMMUNOASSAY ANALYZERS,.
BY REGION, 2024–2026 (USD) 81.
TABLE 17 AVERAGE SELLING PRICE TREND OF IMMUNOASSAY PRODUCTS, BY TYPE,.
2024–2026 (USD) 82.
TABLE 18 IMPORT DATA FOR HS CODE 382200-COMPLIANT PRODUCTS, BY COUNTRY, 2021–2025 (USD MILLION) 83.
TABLE 19 EXPORT DATA FOR HS CODE 382200-COMPLIANT PRODUCTS, BY COUNTRY, 2021–2025 (USD MILLION) 84.
TABLE 20 IMMUNOASSAY MARKET: KEY CONFERENCES & EVENTS, 2026–2027 84.
TABLE 21 US-ADJUSTED RECIPROCAL TARIFF RATES 87.
TABLE 22 KEY PATENTS IN IMMUNOASSAY, 2023–2026 94.
TABLE 23 KEY COMPANIES IMPLEMENTING AI IN IMMUNOASSAY MARKET 97.
TABLE 24 US: CLASSIFICATION AND RISK LEVEL OF IMMUNOASSAY PRODUCTS 98.
TABLE 25 EUROPE: CLASSIFICATION AND RISK LEVEL OF IN VITRO DIAGNOSTIC DEVICES 101.
TABLE 26 RUSSIA: CLASSIFICATION AND RISK LEVEL OF IN VITRO DIAGNOSTIC DEVICES 101.
TABLE 27 JAPAN: CLASSIFICATION OF IN VITRO DIAGNOSTIC REAGENTS 102.
TABLE 28 JAPAN: TIME, COST, AND COMPLEXITY OF REGISTRATION PROCESS 103.
TABLE 29 CHINA: TIME, COST, AND COMPLEXITY OF REGISTRATION PROCESS 103.
TABLE 30 INDONESIA: REGISTRATION PROCESS FOR IN VITRO DIAGNOSTIC DEVICES 104.
TABLE 31 SOUTH KOREA: TIME, COST, AND COMPLEXITY OF REGISTRATION PROCESS 105.
TABLE 32 SAUDI ARABIA: TIME, COST, AND COMPLEXITY OF REGISTRATION PROCESS 106.
TABLE 33 MEXICO: TIME, COST, AND COMPLEXITY OF REGISTRATION PROCESS 107.
TABLE 34 NORTH AMERICA: REGULATORY BODIES, GOVERNMENT AGENCIES,.
AND OTHER ORGANIZATIONS 108.
TABLE 35 EUROPE: REGULATORY BODIES, GOVERNMENT AGENCIES,.
AND OTHER ORGANIZATIONS 109.
TABLE 36 ASIA PACIFIC: REGULATORY BODIES, GOVERNMENT AGENCIES,.
AND OTHER ORGANIZATIONS 109.
TABLE 37 LATIN AMERICA: REGULATORY BODIES, GOVERNMENT AGENCIES,.
AND OTHER ORGANIZATIONS 109.
TABLE 38 REST OF THE WORLD: REGULATORY BODIES, GOVERNMENT AGENCIES,.
AND OTHER ORGANIZATIONS 110.
TABLE 39 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS, BY END USER (%) 113.
TABLE 40 KEY BUYING CRITERIA, BY END USER 114.
TABLE 41 ADOPTION BARRIERS & INTERNAL CHALLENGES 115.
TABLE 42 IMMUNOASSAY MARKET: UNMET NEEDS IN VARIOUS END-USE INDUSTRIES 116.
TABLE 43 IMMUNOASSAY MARKET, BY PRODUCT, 2024–2031 (USD MILLION) 119.
TABLE 44 KEY REAGENTS & KITS AVAILABLE IN MARKET 120.
TABLE 45 IMMUNOASSAY REAGENTS & KITS MARKET, BY REGION,.
2024–2031 (USD MILLION) 121.
TABLE 46 IMMUNOASSAY REAGENTS & KITS MARKET, BY TYPE, 2024–2031 (USD MILLION) 121.
TABLE 47 NORTH AMERICA: IMMUNOASSAY REAGENTS & KITS MARKET,.
BY COUNTRY, 2024–2031 (USD MILLION) 122.
TABLE 48 EUROPE: IMMUNOASSAY REAGENTS & KITS MARKET, BY COUNTRY,.
2024–2031 (USD MILLION) 122.
TABLE 49 ASIA PACIFIC: IMMUNOASSAY REAGENTS & KITS MARKET, BY COUNTRY,.
2024–2031 (USD MILLION) 123.
TABLE 50 LATIN AMERICA: IMMUNOASSAY REAGENTS & KITS MARKET, BY COUNTRY,.
2024–2031 (USD MILLION) 123.
TABLE 51 ELISA REAGENTS & KITS MARKET, BY REGION, 2024–2031 (USD MILLION) 125.
TABLE 52 NORTH AMERICA: ELISA REAGENTS & KITS MARKET, BY COUNTRY,.
2024–2031 (USD MILLION) 125.
TABLE 53 EUROPE: ELISA REAGENTS & KITS MARKET, BY COUNTRY,.
2024–2031 (USD MILLION) 126.
TABLE 54 ASIA PACIFIC: ELISA REAGENTS & KITS MARKET, BY COUNTRY,.
2024–2031 (USD MILLION) 126.
TABLE 55 LATIN AMERICA: ELISA REAGENTS & KITS MARKET, BY COUNTRY,.
2024–2031 (USD MILLION) 127.
TABLE 56 RAPID TEST REAGENTS & KITS MARKET, BY REGION, 2024–2031 (USD MILLION) 128.
TABLE 57 NORTH AMERICA: RAPID TEST REAGENTS & KITS MARKET, BY COUNTRY,.
2024–2031 (USD MILLION) 128.
TABLE 58 EUROPE: RAPID TEST REAGENTS & KITS MARKET, BY COUNTRY,.
2024–2031 (USD MILLION) 129.
TABLE 59 ASIA PACIFIC: RAPID TEST REAGENTS & KITS MARKET, BY COUNTRY,.
2024–2031 (USD MILLION) 129.
TABLE 60 LATIN AMERICA: RAPID TEST REAGENTS & KITS MARKET, BY COUNTRY,.
2024–2031 (USD MILLION) 130.
TABLE 61 CLIA REAGENTS & KITS MARKET, BY REGION, 2024–2031 (USD MILLION) 131.
TABLE 62 NORTH AMERICA: CLIA REAGENTS & KITS MARKET, BY COUNTRY,.
2024–2031 (USD MILLION) 131.
TABLE 63 EUROPE: CLIA REAGENTS & KITS MARKET, BY COUNTRY,.
2024–2031 (USD MILLION) 132.
TABLE 64 ASIA PACIFIC: CLIA REAGENTS & KITS MARKET, BY COUNTRY,.
2024–2031 (USD MILLION) 132.
TABLE 65 LATIN AMERICA: CLIA REAGENTS & KITS MARKET, BY COUNTRY,.
2024–2031 (USD MILLION) 133.
TABLE 66 IFA REAGENTS & KITS MARKET, BY REGION, 2024–2031 (USD MILLION) 133.
TABLE 67 NORTH AMERICA: IFA REAGENTS & KITS MARKET, BY COUNTRY,.
2024–2031 (USD MILLION) 134.
TABLE 68 EUROPE: IFA REAGENTS & KITS MARKET, BY COUNTRY,.
2024–2031 (USD MILLION) 134.
TABLE 69 ASIA PACIFIC: IFA REAGENTS & KITS MARKET, BY COUNTRY,.
2024–2031 (USD MILLION) 135.
TABLE 70 LATIN AMERICA: IFA REAGENTS & KITS MARKET, BY COUNTRY,.
2024–2031 (USD MILLION) 135.
TABLE 71 WESTERN BLOT REAGENTS & KITS MARKET, BY REGION,.
2024–2031 (USD MILLION) 136.
TABLE 72 NORTH AMERICA: WESTERN BLOT REAGENTS & KITS MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 137.
TABLE 73 EUROPE: WESTERN BLOT REAGENTS & KITS MARKET, BY COUNTRY,.
2024–2031 (USD MILLION) 137.
TABLE 74 ASIA PACIFIC: WESTERN BLOT REAGENTS & KITS MARKET, BY COUNTRY,.
2024–2031 (USD MILLION) 138.
TABLE 75 LATIN AMERICA: WESTERN BLOT REAGENTS & KITS MARKET, BY COUNTRY,.
2024–2031 (USD MILLION) 138.
TABLE 76 OTHER REAGENTS & KITS MARKET, BY REGION, 2024–2031 (USD MILLION) 139.
TABLE 77 NORTH AMERICA: OTHER REAGENTS & KITS MARKET, BY COUNTRY,.
2024–2031 (USD MILLION) 139.
TABLE 78 EUROPE: OTHER REAGENTS & KITS MARKET, BY COUNTRY,.
2024–2031 (USD MILLION) 140.
TABLE 79 ASIA PACIFIC: OTHER REAGENTS & KITS MARKET, BY COUNTRY,.
2024–2031 (USD MILLION) 140.
TABLE 80 LATIN AMERICA: OTHER REAGENTS & KITS MARKET, BY COUNTRY,.
2024–2031 (USD MILLION) 141.
TABLE 81 KEY ANALYZERS AVAILABLE IN MARKET 142.
TABLE 82 IMMUNOASSAY ANALYZERS MARKET, BY REGION, 2024–2031 (USD MILLION) 143.
TABLE 83 NORTH AMERICA: IMMUNOASSAY ANALYZERS MARKET, BY COUNTRY,.
2024–2031 (USD MILLION) 143.
TABLE 84 EUROPE: IMMUNOASSAY ANALYZERS MARKET, BY COUNTRY,.
2024–2031 (USD MILLION) 144.
TABLE 85 ASIA PACIFIC: IMMUNOASSAY ANALYZERS MARKET, BY COUNTRY,.
2024–2031 (USD MILLION) 144.
TABLE 86 LATIN AMERICA: IMMUNOASSAY ANALYZERS MARKET, BY COUNTRY,.
2024–2031 (USD MILLION) 145.
TABLE 87 IMMUNOASSAY ANALYZERS MARKET, BY TYPE, 2024–2031 (USD MILLION) 146.
TABLE 88 OPEN-ENDED IMMUNOASSAY SYSTEMS MARKET, BY REGION,.
2024–2031 (USD MILLION) 146.
TABLE 89 NORTH AMERICA: OPEN-ENDED IMMUNOASSAY SYSTEMS MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 147.
TABLE 90 EUROPE: OPEN-ENDED IMMUNOASSAY SYSTEMS MARKET, BY COUNTRY,.
2024–2031 (USD MILLION) 147.
TABLE 91 ASIA PACIFIC: OPEN-ENDED IMMUNOASSAY SYSTEMS MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 148.
TABLE 92 LATIN AMERICA: OPEN-ENDED IMMUNOASSAY SYSTEMS MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 148.
TABLE 93 CLOSED-ENDED IMMUNOASSAY SYSTEMS MARKET, BY REGION,.
2024–2031 (USD MILLION) 149.
TABLE 94 NORTH AMERICA: CLOSED-ENDED IMMUNOASSAY SYSTEMS MARKET,.
BY COUNTRY, 2024–2031 (USD MILLION) 149.
TABLE 95 EUROPE: CLOSED-ENDED IMMUNOASSAY SYSTEMS MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 150.
TABLE 96 ASIA PACIFIC: CLOSED-ENDED IMMUNOASSAY SYSTEMS MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 150.
TABLE 97 LATIN AMERICA: CLOSED-ENDED IMMUNOASSAY SYSTEMS MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 151.
TABLE 98 IMMUNOASSAY ANALYZERS MARKET, BY PURCHASE MODE,.
2024–2031 (USD MILLION) 151.
TABLE 99 IMMUNOASSAY ANALYZERS MARKET FOR RENTAL PURCHASE, BY REGION,.
2024–2031 (USD MILLION) 152.
TABLE 100 NORTH AMERICA: IMMUNOASSAY ANALYZERS MARKET FOR RENTAL PURCHASE, BY COUNTRY, 2024–2031 (USD MILLION) 153.
TABLE 101 EUROPE: IMMUNOASSAY ANALYZERS MARKET FOR RENTAL PURCHASE,.
BY COUNTRY, 2024–2031 (USD MILLION) 153.
TABLE 102 ASIA PACIFIC: IMMUNOASSAY ANALYZERS MARKET FOR RENTAL PURCHASE,.
BY COUNTRY, 2024–2031 (USD MILLION) 154.
TABLE 103 LATIN AMERICA: IMMUNOASSAY ANALYZERS MARKET FOR RENTAL PURCHASE,.
BY COUNTRY, 2024–2031 (USD MILLION) 154.
TABLE 104 IMMUNOASSAY ANALYZERS MARKET FOR OUTRIGHT PURCHASE, BY REGION, 2024–2031 (USD MILLION) 155.
TABLE 105 NORTH AMERICA: IMMUNOASSAY ANALYZERS MARKET FOR OUTRIGHT PURCHASE, BY COUNTRY, 2024–2031 (USD MILLION) 155.
TABLE 106 EUROPE: IMMUNOASSAY ANALYZERS MARKET FOR OUTRIGHT PURCHASE,.
BY COUNTRY, 2024–2031 (USD MILLION) 156.
TABLE 107 ASIA PACIFIC: IMMUNOASSAY ANALYZERS MARKET FOR OUTRIGHT PURCHASE,.
BY COUNTRY, 2024–2031 (USD MILLION) 156.
TABLE 108 LATIN AMERICA: IMMUNOASSAY ANALYZERS MARKET FOR OUTRIGHT PURCHASE, BY COUNTRY, 2024–2031 (USD MILLION) 157.
TABLE 109 IMMUNOASSAY MARKET, BY TECHNOLOGY, 2024–2031 (USD MILLION) 159.
TABLE 110 KEY ELISA TECHNOLOGIES AVAILABLE IN MARKET 160.
TABLE 111 IMMUNOASSAY MARKET FOR ELISA, BY REGION, 2024–2031 (USD MILLION) 161.
TABLE 112 NORTH AMERICA: IMMUNOASSAY MARKET FOR ELISA, BY COUNTRY,.
2024–2031 (USD MILLION) 161.
TABLE 113 EUROPE: IMMUNOASSAY MARKET FOR ELISA, BY COUNTRY,.
2024–2031 (USD MILLION) 162.
TABLE 114 ASIA PACIFIC: IMMUNOASSAY MARKET FOR ELISA, BY COUNTRY,.
2024–2031 (USD MILLION) 162.
TABLE 115 LATIN AMERICA: IMMUNOASSAY MARKET FOR ELISA, BY COUNTRY,.
2024–2031 (USD MILLION) 163.
TABLE 116 IMMUNOASSAY MARKET FOR CLIA, BY REGION, 2024–2031 (USD MILLION) 164.
TABLE 117 NORTH AMERICA: IMMUNOASSAY MARKET FOR CLIA, BY COUNTRY,.
2024–2031 (USD MILLION) 164.
TABLE 118 EUROPE: IMMUNOASSAY MARKET FOR CLIA, BY COUNTRY,.
2024–2031 (USD MILLION) 165.
TABLE 119 ASIA PACIFIC: IMMUNOASSAY MARKET FOR CLIA, BY COUNTRY,.
2024–2031 (USD MILLION) 165.
TABLE 120 LATIN AMERICA: IMMUNOASSAY MARKET FOR CLIA, BY COUNTRY,.
2024–2031 (USD MILLION) 166.
TABLE 121 IMMUNOASSAY MARKET FOR IFA, BY REGION, 2024–2031 (USD MILLION) 167.
TABLE 122 NORTH AMERICA: IMMUNOASSAY MARKET FOR IFA, BY COUNTRY,.
2024–2031 (USD MILLION) 167.
TABLE 123 EUROPE: IMMUNOASSAY MARKET FOR IFA, BY COUNTRY,.
2024–2031 (USD MILLION) 168.
TABLE 124 ASIA PACIFIC: IMMUNOASSAY MARKET FOR IFA, BY COUNTRY,.
2024–2031 (USD MILLION) 168.
TABLE 125 LATIN AMERICA: IMMUNOASSAY MARKET FOR IFA, BY COUNTRY,.
2024–2031 (USD MILLION) 169.
TABLE 126 KEY RAPID TESTS AVAILABLE IN MARKET 169.
TABLE 127 IMMUNOASSAY MARKET FOR RAPID TESTS, BY REGION,.
2024–2031 (USD MILLION) 170.
TABLE 128 NORTH AMERICA: IMMUNOASSAY MARKET FOR RAPID TESTS, BY COUNTRY, 2024–2031 (USD MILLION) 170.
TABLE 129 EUROPE: IMMUNOASSAY MARKET FOR RAPID TESTS, BY COUNTRY,.
2024–2031 (USD MILLION) 171.
TABLE 130 ASIA PACIFIC: IMMUNOASSAY MARKET FOR RAPID TESTS, BY COUNTRY,.
2024–2031 (USD MILLION) 171.
TABLE 131 LATIN AMERICA: IMMUNOASSAY MARKET FOR RAPID TESTS, BY COUNTRY,.
2024–2031 (USD MILLION) 172.
TABLE 132 KEY WESTERN BLOTTING SYSTEMS AVAILABLE IN MARKET 172.
TABLE 133 IMMUNOASSAY MARKET FOR WESTERN BLOTTING, BY REGION,.
2024–2031 (USD MILLION) 173.
TABLE 134 NORTH AMERICA: IMMUNOASSAY MARKET FOR WESTERN BLOTTING,.
BY COUNTRY, 2024–2031 (USD MILLION) 173.
TABLE 135 EUROPE: IMMUNOASSAY MARKET FOR WESTERN BLOTTING, BY COUNTRY,.
2024–2031 (USD MILLION) 174.
TABLE 136 ASIA PACIFIC: IMMUNOASSAY MARKET FOR WESTERN BLOTTING, BY COUNTRY, 2024–2031 (USD MILLION) 174.
TABLE 137 LATIN AMERICA: IMMUNOASSAY MARKET FOR WESTERN BLOTTING, BY COUNTRY, 2024–2031 (USD MILLION) 175.
TABLE 138 IMMUNOASSAY MARKET FOR OTHER TECHNOLOGIES, BY REGION,.
2024–2031 (USD MILLION) 176.
TABLE 139 NORTH AMERICA: IMMUNOASSAY MARKET FOR OTHER TECHNOLOGIES,.
BY COUNTRY, 2024–2031 (USD MILLION) 176.
TABLE 140 EUROPE: IMMUNOASSAY MARKET FOR OTHER TECHNOLOGIES, BY COUNTRY, 2024–2031 (USD MILLION) 177.
TABLE 141 ASIA PACIFIC: IMMUNOASSAY MARKET FOR OTHER TECHNOLOGIES,.
BY COUNTRY, 2024–2031 (USD MILLION) 177.
TABLE 142 LATIN AMERICA: IMMUNOASSAY MARKET FOR OTHER TECHNOLOGIES,.
BY COUNTRY, 2024–2031 (USD MILLION) 178.
TABLE 143 IMMUNOASSAY MARKET, BY SPECIMEN, 2024–2031 (USD MILLION) 180.
TABLE 144 IMMUNOASSAY MARKET FOR BLOOD SPECIMENS, BY REGION,.
2024–2031 (USD MILLION) 181.
TABLE 145 NORTH AMERICA: IMMUNOASSAY MARKET FOR BLOOD SPECIMENS, BY COUNTRY, 2024–2031 (USD MILLION) 182.
TABLE 146 EUROPE: IMMUNOASSAY MARKET FOR BLOOD SPECIMENS, BY COUNTRY,.
2024–2031 (USD MILLION) 182.
TABLE 147 ASIA PACIFIC: IMMUNOASSAY MARKET FOR BLOOD SPECIMENS, BY COUNTRY, 2024–2031 (USD MILLION) 183.
TABLE 148 LATIN AMERICA: IMMUNOASSAY MARKET FOR BLOOD SPECIMENS, BY COUNTRY, 2024–2031 (USD MILLION) 183.
TABLE 149 IMMUNOASSAY MARKET FOR SALIVA SPECIMENS, BY REGION,.
2024–2031 (USD MILLION) 184.
TABLE 150 NORTH AMERICA: IMMUNOASSAY MARKET FOR SALIVA SPECIMENS, BY COUNTRY, 2024–2031 (USD MILLION) 185.
TABLE 151 EUROPE: IMMUNOASSAY MARKET FOR SALIVA SPECIMENS, BY COUNTRY,.
2024–2031 (USD MILLION) 185.
TABLE 152 ASIA PACIFIC: IMMUNOASSAY MARKET FOR SALIVA SPECIMENS, BY COUNTRY, 2024–2031 (USD MILLION) 186.
TABLE 153 LATIN AMERICA: IMMUNOASSAY MARKET FOR SALIVA SPECIMENS, BY COUNTRY, 2024–2031 (USD MILLION) 186.
TABLE 154 IMMUNOASSAY MARKET FOR URINE SPECIMENS, BY REGION,.
2024–2031 (USD MILLION) 187.
TABLE 155 NORTH AMERICA: IMMUNOASSAY MARKET FOR URINE SPECIMENS, BY COUNTRY, 2024–2031 (USD MILLION) 188.
TABLE 156 EUROPE: IMMUNOASSAY MARKET FOR URINE SPECIMENS, BY COUNTRY,.
2024–2031 (USD MILLION) 188.
TABLE 157 ASIA PACIFIC: IMMUNOASSAY MARKET FOR URINE SPECIMENS, BY COUNTRY, 2024–2031 (USD MILLION) 189.
TABLE 158 LATIN AMERICA: IMMUNOASSAY MARKET FOR URINE SPECIMENS, BY COUNTRY, 2024–2031 (USD MILLION) 189.
TABLE 159 IMMUNOASSAY MARKET FOR OTHER SPECIMENS, BY REGION,.
2024–2031 (USD MILLION) 190.
TABLE 160 NORTH AMERICA: IMMUNOASSAY MARKET FOR OTHER SPECIMENS, BY COUNTRY, 2024–2031 (USD MILLION) 191.
TABLE 161 EUROPE: IMMUNOASSAY MARKET FOR OTHER SPECIMENS, BY COUNTRY,.
2024–2031 (USD MILLION) 191.
TABLE 162 ASIA PACIFIC: IMMUNOASSAY MARKET FOR OTHER SPECIMENS, BY COUNTRY, 2024–2031 (USD MILLION) 192.
TABLE 163 LATIN AMERICA: IMMUNOASSAY MARKET FOR OTHER SPECIMENS, BY COUNTRY, 2024–2031 (USD MILLION) 192.
TABLE 164 IMMUNOASSAY MARKET, BY APPLICATION, 2024–2031 (USD MILLION) 194.
TABLE 165 IMMUNOASSAY MARKET FOR INFECTIOUS DISEASES, BY REGION, 2024–2031 (USD MILLION) 195.
TABLE 166 NORTH AMERICA: IMMUNOASSAY MARKET FOR INFECTIOUS DISEASES,.
BY COUNTRY, 2024–2031 (USD MILLION) 196.
TABLE 167 EUROPE: IMMUNOASSAY MARKET FOR INFECTIOUS DISEASES, BY COUNTRY, 2024–2031 (USD MILLION) 196.
TABLE 168 ASIA PACIFIC: IMMUNOASSAY MARKET FOR INFECTIOUS DISEASES, BY COUNTRY, 2024–2031 (USD MILLION) 197.
TABLE 169 LATIN AMERICA: IMMUNOASSAY MARKET FOR INFECTIOUS DISEASES,.
BY COUNTRY, 2024–2031 (USD MILLION) 197.
TABLE 170 IMMUNOASSAY MARKET FOR ENDOCRINOLOGY, BY REGION,.
2024–2031 (USD MILLION) 198.
TABLE 171 NORTH AMERICA: IMMUNOASSAY MARKET FOR ENDOCRINOLOGY,.
BY COUNTRY, 2024–2031 (USD MILLION) 199.
TABLE 172 EUROPE: IMMUNOASSAY MARKET FOR ENDOCRINOLOGY, BY COUNTRY,.
2024–2031 (USD MILLION) 199.
TABLE 173 ASIA PACIFIC: IMMUNOASSAY MARKET FOR ENDOCRINOLOGY, BY COUNTRY, 2024–2031 (USD MILLION) 200.
TABLE 174 LATIN AMERICA: IMMUNOASSAY MARKET FOR ENDOCRINOLOGY, BY COUNTRY, 2024–2031 (USD MILLION) 200.
TABLE 175 KEY PRODUCTS AVAILABLE FOR CARDIOLOGY APPLICATIONS 202.
TABLE 176 IMMUNOASSAY MARKET FOR CARDIOLOGY, BY REGION,.
2024–2031 (USD MILLION) 202.
TABLE 177 NORTH AMERICA: IMMUNOASSAY MARKET FOR CARDIOLOGY, BY COUNTRY, 2024–2031 (USD MILLION) 203.
TABLE 178 EUROPE: IMMUNOASSAY MARKET FOR CARDIOLOGY, BY COUNTRY,.
2024–2031 (USD MILLION) 203.
TABLE 179 ASIA PACIFIC: IMMUNOASSAY MARKET FOR CARDIOLOGY, BY COUNTRY,.
2024–2031 (USD MILLION) 204.
TABLE 180 LATIN AMERICA: IMMUNOASSAY MARKET FOR CARDIOLOGY, BY COUNTRY,.
2024–2031 (USD MILLION) 204.
TABLE 181 IMMUNOASSAY MARKET FOR AUTOIMMUNE DISORDERS, BY REGION,.
2024–2031 (USD MILLION) 205.
TABLE 182 NORTH AMERICA: IMMUNOASSAY MARKET FOR AUTOIMMUNE DISORDERS,.
BY COUNTRY, 2024–2031 (USD MILLION) 206.
TABLE 183 EUROPE: IMMUNOASSAY MARKET FOR AUTOIMMUNE DISORDERS, BY COUNTRY, 2024–2031 (USD MILLION) 206.
TABLE 184 ASIA PACIFIC: IMMUNOASSAY MARKET FOR AUTOIMMUNE DISORDERS,.
BY COUNTRY, 2024–2031 (USD MILLION) 207.
TABLE 185 LATIN AMERICA: IMMUNOASSAY MARKET FOR AUTOIMMUNE DISORDERS,.
BY COUNTRY, 2024–2031 (USD MILLION) 207.
TABLE 186 IMMUNOASSAY MARKET FOR ALLERGY DIAGNOSTICS, BY REGION,.
2024–2031 (USD MILLION) 208.
TABLE 187 NORTH AMERICA: IMMUNOASSAY MARKET FOR ALLERGY DIAGNOSTICS,.
BY COUNTRY, 2024–2031 (USD MILLION) 209.
TABLE 188 EUROPE: IMMUNOASSAY MARKET FOR ALLERGY DIAGNOSTICS, BY COUNTRY, 2024–2031 (USD MILLION) 209.
TABLE 189 ASIA PACIFIC: IMMUNOASSAY MARKET FOR ALLERGY DIAGNOSTICS,.
BY COUNTRY, 2024–2031 (USD MILLION) 210.
TABLE 190 LATIN AMERICA: IMMUNOASSAY MARKET FOR ALLERGY DIAGNOSTICS,.
BY COUNTRY, 2024–2031 (USD MILLION) 210.
TABLE 191 IMMUNOASSAY MARKET FOR ONCOLOGY, BY REGION, 2024–2031 (USD MILLION) 212.
TABLE 192 NORTH AMERICA: IMMUNOASSAY MARKET FOR ONCOLOGY, BY COUNTRY,.
2024–2031 (USD MILLION) 212.
TABLE 193 EUROPE: IMMUNOASSAY MARKET FOR ONCOLOGY, BY COUNTRY,.
2024–2031 (USD MILLION) 213.
TABLE 194 ASIA PACIFIC: IMMUNOASSAY MARKET FOR ONCOLOGY, BY COUNTRY,.
2024–2031 (USD MILLION) 213.
TABLE 195 LATIN AMERICA: IMMUNOASSAY MARKET FOR ONCOLOGY, BY COUNTRY,.
2024–2031 (USD MILLION) 214.
TABLE 196 KEY PRODUCTS AVAILABLE FOR BONE & MINERAL DISORDERS 215.
TABLE 197 IMMUNOASSAY MARKET FOR BONE & MINERAL DISORDERS, BY REGION,.
2024–2031 (USD MILLION) 215.
TABLE 198 NORTH AMERICA: IMMUNOASSAY MARKET FOR BONE & MINERAL DISORDERS,.
BY COUNTRY, 2024–2031 (USD MILLION) 216.
TABLE 199 EUROPE: IMMUNOASSAY MARKET FOR BONE & MINERAL DISORDERS,.
BY COUNTRY, 2024–2031 (USD MILLION) 216.
TABLE 200 ASIA PACIFIC: IMMUNOASSAY MARKET FOR BONE & MINERAL DISORDERS,.
BY COUNTRY, 2024–2031 (USD MILLION) 217.
TABLE 201 LATIN AMERICA: IMMUNOASSAY MARKET FOR BONE & MINERAL DISORDERS,.
BY COUNTRY, 2024–2031 (USD MILLION) 217.
TABLE 202 KEY PRODUCTS AVAILABLE FOR DRUG MONITORING & TESTING 218.
TABLE 203 KEY IMMUNOASSAY PRODUCTS AVAILABLE FOR DRUG MONITORING & TESTING 219.
TABLE 204 IMMUNOASSAY MARKET FOR DRUG MONITORING & TESTING, BY REGION,.
2024–2031 (USD MILLION) 219.
TABLE 205 NORTH AMERICA: IMMUNOASSAY MARKET FOR DRUG MONITORING & TESTING, BY COUNTRY, 2024–2031 (USD MILLION) 219.
TABLE 206 EUROPE: IMMUNOASSAY MARKET FOR DRUG MONITORING & TESTING,.
BY COUNTRY, 2024–2031 (USD MILLION) 220.
TABLE 207 ASIA PACIFIC: IMMUNOASSAY MARKET FOR DRUG MONITORING & TESTING,.
BY COUNTRY, 2024–2031 (USD MILLION) 220.
TABLE 208 LATIN AMERICA: IMMUNOASSAY MARKET FOR DRUG MONITORING & TESTING,.
BY COUNTRY, 2024–2031 (USD MILLION) 221.
TABLE 209 IMMUNOASSAY MARKET FOR BLOOD SCREENING, BY REGION,.
2024–2031 (USD MILLION) 222.
TABLE 210 NORTH AMERICA: IMMUNOASSAY MARKET FOR BLOOD SCREENING, BY COUNTRY, 2024–2031 (USD MILLION) 222.
TABLE 211 EUROPE: IMMUNOASSAY MARKET FOR BLOOD SCREENING, BY COUNTRY,.
2024–2031 (USD MILLION) 223.
TABLE 212 ASIA PACIFIC: IMMUNOASSAY MARKET FOR BLOOD SCREENING, BY COUNTRY, 2024–2031 (USD MILLION) 223.
TABLE 213 LATIN AMERICA: IMMUNOASSAY MARKET FOR BLOOD SCREENING, BY COUNTRY, 2024–2031 (USD MILLION) 224.
TABLE 214 KEY PRODUCTS AVAILABLE FOR NEWBORN SCREENING 224.
TABLE 215 IMMUNOASSAY MARKET FOR NEWBORN SCREENING, BY REGION,.
2024–2031 (USD MILLION) 225.
TABLE 216 NORTH AMERICA: IMMUNOASSAY MARKET FOR NEWBORN SCREENING,.
BY COUNTRY, 2024–2031 (USD MILLION) 225.
TABLE 217 EUROPE: IMMUNOASSAY MARKET FOR NEWBORN SCREENING, BY COUNTRY, 2024–2031 (USD MILLION) 226.
TABLE 218 ASIA PACIFIC: IMMUNOASSAY MARKET FOR NEWBORN SCREENING, BY COUNTRY, 2024–2031 (USD MILLION) 226.
TABLE 219 LATIN AMERICA: IMMUNOASSAY MARKET FOR NEWBORN SCREENING,.
BY COUNTRY, 2024–2031 (USD MILLION) 227.
TABLE 220 IMMUNOASSAY MARKET FOR OTHER APPLICATIONS, BY REGION,.
2024–2031 (USD MILLION) 228.
TABLE 221 NORTH AMERICA: IMMUNOASSAY MARKET FOR OTHER APPLICATIONS,.
BY COUNTRY, 2024–2031 (USD MILLION) 228.
TABLE 222 EUROPE: IMMUNOASSAY MARKET FOR OTHER APPLICATIONS, BY COUNTRY, 2024–2031 (USD MILLION) 229.
TABLE 223 ASIA PACIFIC: IMMUNOASSAY MARKET FOR OTHER APPLICATIONS, BY COUNTRY, 2024–2031 (USD MILLION) 229.
TABLE 224 LATIN AMERICA: IMMUNOASSAY MARKET FOR OTHER APPLICATIONS,.
BY COUNTRY, 2024–2031 (USD MILLION) 230.
TABLE 225 IMMUNOASSAY MARKET, BY END USER, 2024–2031 (USD MILLION) 232.
TABLE 226 IMMUNOASSAY MARKET FOR HOSPITALS & CLINICS, BY REGION,.
2024–2031 (USD MILLION) 233.
TABLE 227 NORTH AMERICA: IMMUNOASSAY MARKET FOR HOSPITALS & CLINICS,.
BY COUNTRY, 2024–2031 (USD MILLION) 234.
TABLE 228 EUROPE: IMMUNOASSAY MARKET FOR HOSPITALS & CLINICS, BY COUNTRY, 2024–2031 (USD MILLION) 234.
TABLE 229 ASIA PACIFIC: IMMUNOASSAY MARKET FOR HOSPITALS & CLINICS,.
BY COUNTRY, 2024–2031 (USD MILLION) 235.
TABLE 230 LATIN AMERICA: IMMUNOASSAY MARKET FOR HOSPITALS & CLINICS,.
BY COUNTRY, 2024–2031 (USD MILLION) 235.
TABLE 231 IMMUNOASSAY MARKET FOR CLINICAL LABORATORIES, BY REGION,.
2024–2031 (USD MILLION) 237.
TABLE 232 NORTH AMERICA: IMMUNOASSAY MARKET FOR CLINICAL LABORATORIES,.
BY COUNTRY, 2024–2031 (USD MILLION) 237.
TABLE 233 EUROPE: IMMUNOASSAY MARKET FOR CLINICAL LABORATORIES, BY COUNTRY, 2024–2031 (USD MILLION) 238.
TABLE 234 ASIA PACIFIC: IMMUNOASSAY MARKET FOR CLINICAL LABORATORIES,.
BY COUNTRY, 2024–2031 (USD MILLION) 238.
TABLE 235 LATIN AMERICA: IMMUNOASSAY MARKET FOR CLINICAL LABORATORIES,.
BY COUNTRY, 2024–2031 (USD MILLION) 239.
TABLE 236 IMMUNOASSAY MARKET FOR HOME CARE SETTINGS, BY REGION,.
2024–2031 (USD MILLION) 240.
TABLE 237 NORTH AMERICA: IMMUNOASSAY MARKET FOR HOME CARE SETTINGS,.
BY COUNTRY, 2024–2031 (USD MILLION) 240.
TABLE 238 EUROPE: IMMUNOASSAY MARKET FOR HOME CARE SETTINGS, BY COUNTRY, 2024–2031 (USD MILLION) 241.
TABLE 239 ASIA PACIFIC: IMMUNOASSAY MARKET FOR HOME CARE SETTINGS, BY COUNTRY, 2024–2031 (USD MILLION) 241.
TABLE 240 LATIN AMERICA: IMMUNOASSAY MARKET FOR HOME CARE SETTINGS,.
BY COUNTRY, 2024–2031 (USD MILLION) 242.
TABLE 241 IMMUNOASSAY MARKET FOR BLOOD BANKS, BY REGION,.
2024–2031 (USD MILLION) 243.
TABLE 242 NORTH AMERICA: IMMUNOASSAY MARKET FOR BLOOD BANKS, BY COUNTRY, 2024–2031 (USD MILLION) 243.
TABLE 243 EUROPE: IMMUNOASSAY MARKET FOR BLOOD BANKS, BY COUNTRY,.
2024–2031 (USD MILLION) 244.
TABLE 244 ASIA PACIFIC: IMMUNOASSAY MARKET FOR BLOOD BANKS, BY COUNTRY,.
2024–2031 (USD MILLION) 244.
TABLE 245 LATIN AMERICA: IMMUNOASSAY MARKET FOR BLOOD BANKS, BY COUNTRY, 2024–2031 (USD MILLION) 245.
TABLE 246 IMMUNOASSAY MARKET, BY REGION, 2024–2031 (USD MILLION) 247.
TABLE 247 NORTH AMERICA: IMMUNOASSAY MARKET, BY COUNTRY,.
2024–2031 (USD MILLION) 249.
TABLE 248 NORTH AMERICA: IMMUNOASSAY MARKET, BY PRODUCT,.
2024–2031 (USD MILLION) 249.
TABLE 249 NORTH AMERICA: IMMUNOASSAY REAGENTS & KITS MARKET, BY TYPE,.
2024–2031 (USD MILLION) 250.
TABLE 250 NORTH AMERICA: IMMUNOASSAY ANALYZERS MARKET, BY TYPE,.
2024–2031 (USD MILLION) 250.
TABLE 251 NORTH AMERICA: IMMUNOASSAY ANALYZERS MARKET, BY PURCHASE MODE, 2024–2031 (USD MILLION) 251.
TABLE 252 NORTH AMERICA: IMMUNOASSAY MARKET, BY TECHNOLOGY,.
2024–2031 (USD MILLION) 251.
TABLE 253 NORTH AMERICA: IMMUNOASSAY MARKET, BY SPECIMEN,.
2024–2031 (USD MILLION) 252.
TABLE 254 NORTH AMERICA: IMMUNOASSAY MARKET, BY APPLICATION,.
2024–2031 (USD MILLION) 252.
TABLE 255 NORTH AMERICA: IMMUNOASSAY MARKET, BY END USER,.
2024–2031 (USD MILLION) 253.
TABLE 256 US: NUMBER OF IN VITRO DIAGNOSTIC TESTS CONDUCTED,.
2022–2031 (BILLION UNITS) 254.
TABLE 257 US: IMMUNOASSAY MARKET, BY PRODUCT, 2024–2031 (USD MILLION) 255.
TABLE 258 US: IMMUNOASSAY REAGENTS & KITS MARKET, BY TYPE,.
2024–2031 (USD MILLION) 255.
TABLE 259 US: IMMUNOASSAY ANALYZERS MARKET, BY TYPE, 2024–2031 (USD MILLION) 256.
TABLE 260 US: IMMUNOASSAY ANALYZERS MARKET, BY PURCHASE MODE,.
2024–2031 (USD MILLION) 256.
TABLE 261 US: IMMUNOASSAY MARKET, BY TECHNOLOGY, 2024–2031 (USD MILLION) 257.
TABLE 262 US: IMMUNOASSAY MARKET, BY SPECIMEN, 2024–2031 (USD MILLION) 257.
TABLE 263 US: IMMUNOASSAY MARKET, BY APPLICATION, 2024–2031 (USD MILLION) 258.
TABLE 264 US: IMMUNOASSAY MARKET, BY END USER, 2024–2031 (USD MILLION) 258.
TABLE 265 CANADA: ESTIMATED PREVALENCE OF DIABETES, 2025 VS. 2034 259.
TABLE 266 CANADA: IMMUNOASSAY MARKET, BY PRODUCT, 2024–2031 (USD MILLION) 260.
TABLE 267 CANADA: IMMUNOASSAY REAGENTS & KITS MARKET, BY TYPE,.
2024–2031 (USD MILLION) 260.
TABLE 268 CANADA: IMMUNOASSAY ANALYZERS MARKET, BY TYPE,.
2024–2031 (USD MILLION) 261.
TABLE 269 CANADA: IMMUNOASSAY ANALYZERS MARKET, BY PURCHASE MODE,.
2024–2031 (USD MILLION) 261.
TABLE 270 CANADA: IMMUNOASSAY MARKET, BY TECHNOLOGY, 2024–2031 (USD MILLION) 262.
TABLE 271 CANADA: IMMUNOASSAY MARKET, BY SPECIMEN, 2024–2031 (USD MILLION) 262.
TABLE 272 CANADA: IMMUNOASSAY MARKET, BY APPLICATION, 2024–2031 (USD MILLION) 263.
TABLE 273 CANADA: IMMUNOASSAY MARKET, BY END USER, 2024–2031 (USD MILLION) 263.
TABLE 274 EUROPE: IMMUNOASSAY MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 264.
TABLE 275 EUROPE: IMMUNOASSAY MARKET, BY PRODUCT, 2024–2031 (USD MILLION) 265.
TABLE 276 EUROPE: IMMUNOASSAY REAGENTS & KITS MARKET, BY TYPE,.
2024–2031 (USD MILLION) 265.
TABLE 277 EUROPE: IMMUNOASSAY ANALYZERS MARKET, BY TYPE,.
2024–2031 (USD MILLION) 266.
TABLE 278 EUROPE: IMMUNOASSAY ANALYZERS MARKET, BY PURCHASE MODE,.
2024–2031 (USD MILLION) 266.
TABLE 279 EUROPE: IMMUNOASSAY MARKET, BY TECHNOLOGY, 2024–2031 (USD MILLION) 267.
TABLE 280 EUROPE: IMMUNOASSAY MARKET, BY SPECIMEN, 2024–2031 (USD MILLION) 267.
TABLE 281 EUROPE: IMMUNOASSAY MARKET, BY APPLICATION, 2024–2031 (USD MILLION) 268.
TABLE 282 EUROPE: IMMUNOASSAY MARKET, BY END USER, 2024–2031 (USD MILLION) 268.
TABLE 283 GERMANY: IMMUNOASSAY MARKET, BY PRODUCT, 2024–2031 (USD MILLION) 269.
TABLE 284 GERMANY: IMMUNOASSAY REAGENTS & KITS MARKET, BY TYPE,.
2024–2031 (USD MILLION) 270.
TABLE 285 GERMANY: IMMUNOASSAY ANALYZERS MARKET, BY TYPE,.
2024–2031 (USD MILLION) 270.
TABLE 286 GERMANY: IMMUNOASSAY ANALYZERS MARKET, BY PURCHASE MODE,.
2024–2031 (USD MILLION) 271.
TABLE 287 GERMANY: IMMUNOASSAY MARKET, BY TECHNOLOGY,.
2024–2031 (USD MILLION) 271.
TABLE 288 GERMANY: IMMUNOASSAY MARKET, BY SPECIMEN, 2024–2031 (USD MILLION) 272.
TABLE 289 GERMANY: IMMUNOASSAY MARKET, BY APPLICATION, 2024–2031 (USD MILLION) 272.
TABLE 290 GERMANY: IMMUNOASSAY MARKET, BY END USER, 2024–2031 (USD MILLION) 273.
TABLE 291 ITALY: IMMUNOASSAY MARKET, BY PRODUCT, 2024–2031 (USD MILLION) 274.
TABLE 292 ITALY: IMMUNOASSAY REAGENTS & KITS MARKET, BY TYPE,.
2024–2031 (USD MILLION) 274.
TABLE 293 ITALY: IMMUNOASSAY ANALYZERS MARKET, BY TYPE, 2024–2031 (USD MILLION) 275.
TABLE 294 ITALY: IMMUNOASSAY ANALYZERS MARKET, BY PURCHASE MODE,.
2024–2031 (USD MILLION) 275.
TABLE 295 ITALY: IMMUNOASSAY MARKET, BY TECHNOLOGY, 2024–2031 (USD MILLION) 276.
TABLE 296 ITALY: IMMUNOASSAY MARKET, BY SPECIMEN, 2024–2031 (USD MILLION) 276.
TABLE 297 ITALY: IMMUNOASSAY MARKET, BY APPLICATION, 2024–2031 (USD MILLION) 277.
TABLE 298 ITALY: IMMUNOASSAY MARKET, BY END USER, 2024–2031 (USD MILLION) 277.
TABLE 299 FRANCE: IMMUNOASSAY MARKET, BY PRODUCT, 2024–2031 (USD MILLION) 278.
TABLE 300 FRANCE: IMMUNOASSAY REAGENTS & KITS MARKET, BY TYPE,.
2024–2031 (USD MILLION) 279.
TABLE 301 FRANCE: IMMUNOASSAY ANALYZERS MARKET, BY TYPE,.
2024–2031 (USD MILLION) 279.
TABLE 302 FRANCE: IMMUNOASSAY ANALYZERS MARKET, BY PURCHASE MODE,.
2024–2031 (USD MILLION) 280.
TABLE 303 FRANCE: IMMUNOASSAY MARKET, BY TECHNOLOGY, 2024–2031 (USD MILLION) 280.
TABLE 304 FRANCE: IMMUNOASSAY MARKET, BY SPECIMEN, 2024–2031 (USD MILLION) 281.
TABLE 305 FRANCE: IMMUNOASSAY MARKET, BY APPLICATION, 2024–2031 (USD MILLION) 281.
TABLE 306 FRANCE: IMMUNOASSAY MARKET, BY END USER, 2024–2031 (USD MILLION) 282.
TABLE 307 UK: IMMUNOASSAY MARKET, BY PRODUCT, 2024–2031 (USD MILLION) 283.
TABLE 308 UK: IMMUNOASSAY REAGENTS & KITS MARKET, BY TYPE,.
2024–2031 (USD MILLION) 284.

 

ページTOPに戻る


 

Summary

The global immunoassay market is estimated to be valued at USD 31.65 billion in 2026 and is projected to reach USD 44.49 billion by 2031, registering a CAGR of 7.0% during the forecast period. Market growth is primarily driven by the rising prevalence of chronic and infectious diseases, continued technological advancements in immunoassay systems, supportive government initiatives, and increasing demand for drug and alcohol screening driven by stringent regulatory requirements.

By product, the reagents & kits segment accounted for the largest share of the immunoassay market in 2025.
Based on product type, the global immunoassay market is segmented into reagents & kits and analyzers. Among these, reagents & kits are expected to account for the largest share of the market, primarily owing to their recurring use across a broad range of diagnostic applications. The growing volume of immunoassay testing, coupled with the continuous requirement for consumable reagents and kits, supports sustained demand for this segment. In addition, the increasing availability of high-performance products that offer enhanced diagnostic accuracy, reliability, and workflow efficiency is contributing to their widespread adoption and supporting segment growth.

By technology, the chemiluminescence immunoassay segment is expected to grow at a considerable rate during the forecast period.
The immunoassay market is segmented by technology into ELISA, chemiluminescence immunoassay (CLIA), immunofluorescence assay (IFA), rapid tests, ELISpot, western blotting, and other technologies. Among these, the CLIA segment is expected to grow significantly during the forecast period, driven by its increasing adoption in diagnosing and monitoring chronic and infectious diseases. CLIA offers several advantages over conventional techniques, including high sensitivity and specificity, a broad dynamic range, faster turnaround times, and lower background interference. These benefits, along with its suitability for automated and high-throughput testing, are expected to support the increasing adoption of CLIA in clinical diagnostic applications.

Asia Pacific is expected to register the fastest growth rate in the immunoassay market between 2026 and 2031.
The global immunoassay market is segmented geographically into North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa. Among these regions, Asia Pacific is expected to register the highest growth during the 2026–2031 forecast period. This growth is attributed to the region’s large and expanding patient population, increasing prevalence of chronic and infectious diseases, growing awareness of early disease diagnosis, and continued improvements in healthcare infrastructure. In addition, increasing healthcare investments and the adoption of advanced diagnostic technologies across countries such as China, India, and Southeast Asian nations are expected to further support market growth in the region.

The breakdown of primary participants in the immunoassay market is as follows:
- By Company Type: Tier 1 (32%), Tier 2 (41%), and Tier 3 (27%)
- By Designation: C-level Executives (30%), Directors (26%), and Others (44%)
- By Region: North America (53%), Europe (21%), Asia Pacific (17%), Latin America (6%), and the Middle East & Africa (4%)

Key players in the immunoassay market are Abbott Laboratories (US), F. Hoffmann-La Roche Ltd (Switzerland), Siemens Healthineers AG (Germany), Danaher Corporation (US), Thermo Fisher Scientific, Inc. (US), PerkinElmer, Inc. (US), Becton, Dickinson and Company (US), DiaSorin S.p.A. (Italy), Bio-Rad Laboratories, Inc. (US), QuidelOrtho Corporation (US), bioMérieux (France), QIAGEN N.V. (Germany), Sysmex Corporation (Japan), Shenzhen Mindray Bio-Medical Electronics Co., Ltd. (China), Agilent Technologies (US), Merck KGaA (Germany), Meridian Bioscience (US), Bio-Techne (US), Cellabs (Australia), Abnova Corporation (Taiwan), J. Mitra & Co. Pvt. Ltd. (India), Tosoh Corporation (Japan), Cell Sciences (US), Enzo Biochem (US), Creative Diagnostics (US), Boster Biological Technology (US), Elabscience (US), WAK-Chemie Medical GmbH (Germany), SeraCare (US), Epitope Diagnostics Inc. (US), Kamiya Biomedical Company (US), Gyros Protein Technologies (Sweden), Trivitron Healthcare (India), InBios International Inc. (US), and Maccura Biotechnology Co., Ltd. (China).

Research Coverage:
This research report categorizes the immunoassay market by product (reagents & kits and analyzers), specimen type (blood, urine, saliva, and other specimens), technology (enzyme-linked immunosorbent assays, rapid tests, chemiluminescence immunoassay, immunofluorescence assay, enzyme-linked immunospot, western blotting, and other technologies), application (infectious diseases, blood screening, oncology, endocrinology, bone and mineral disorders, autoimmune disorders, cardiology, drug monitoring and testing, allergy diagnostics, newborn screening, and other applications), end user (clinical laboratories, hospitals & clinics, blood banks, and home care settings), and region (North America, Europe, Asia Pacific, Middle East & Africa, and Latin America).

The report covers detailed information on major factors, such as drivers, restraints, opportunities, and challenges influencing immunoassay market growth. A detailed analysis of key industry players provides insights into their business overview, solutions, and key strategies, including partnerships, collaborations, expansions, agreements, product launches, and recent market developments. This report covers the competitive analysis of upcoming startups in the immunoassay ecosystem.

Reasons to Buy This Report:
The report will help leaders/new entrants in this market by providing revenue estimates for the overall immunoassay market and its subsegments. This report will help stakeholders understand the competitive landscape and gain deeper insights to better position their businesses and plan suitable go-to-market strategies. The report also helps stakeholders understand the market pulse and provides information on key drivers, restraints, opportunities, and challenges.

The report provides insights into the following pointers:
- Analysis of key drivers (increasing incidence of chronic and infectious diseases, increased demand for blood donations in healthcare systems and surgical procedures, growth in biotechnology and biopharmaceutical industries, supportive government regulatory policies and initiatives, increasing adoption of immunoassay-based POC and rapid testing, and increasing consumption of drugs, alcohol, and cannabis), restraints (stringent requirements for approval of immunoassay instruments and consumables and technical hurdles of immunoassay kits), opportunities (increasing growth opportunities in emerging economies, focus on companion diagnostics, development of condition-specific biomarkers and tests, integration of microfluidics in immunoassays, and improving immunoassay diagnostic technologies), and challenges (design challenges and low quality of antibodies and dearth of skilled professionals) influencing the immunoassay market growth.
- Product Development/Innovation: Detailed insights on upcoming technologies, research & development activities, and product launches in the immunoassay market.
- Market Development: Comprehensive information about lucrative markets; the report analyzes the immunoassay market across varied regions.
- Market Diversification: Exhaustive information about new products, untapped geographies, recent developments, and investments in the immunoassay market.
- Competitive Assessment: In-depth assessment of market shares, growth strategies, and product offerings of leading players like Abbott Laboratories (US), F. Hoffmann-La Roche Ltd (Switzerland), Siemens Healthineers AG (Germany), Danaher Corporation (US), and Bio-Rad (US), among others, in the immunoassay market.



ページTOPに戻る


Table of Contents

1 INTRODUCTION 38
1.1 STUDY OBJECTIVES 38
1.2 MARKET DEFINITION 38
1.3 STUDY SCOPE 39
1.3.1 MARKET SEGMENTATION & REGIONAL SCOPE 39
1.3.2 INCLUSIONS & EXCLUSIONS 40
1.3.3 YEARS CONSIDERED 41
1.3.4 CURRENCY CONSIDERED 41
1.4 STAKEHOLDERS 41
1.5 SUMMARY OF CHANGES 42

2 EXECUTIVE SUMMARY 43
2.1 KEY INSIGHTS & MARKET HIGHLIGHTS 43
2.2 KEY MARKET PARTICIPANTS: INSIGHTS & STRATEGIC DEVELOPMENTS 44
2.3 DISRUPTIVE TRENDS SHAPING MARKET GROWTH 45
2.4 HIGH-GROWTH SEGMENTS & EMERGING FRONTIERS 46
2.5 SNAPSHOT: GLOBAL MARKET SIZE, GROWTH RATE, AND FORECAST 47

3 PREMIUM INSIGHTS 48
3.1 IMMUNOASSAY MARKET OVERVIEW 48
3.2 IMMUNOASSAY MARKET, BY PRODUCT, 2026 VS. 2031 49
3.3 IMMUNOASSAY MARKET, BY TECHNOLOGY, 2026 VS. 2031 49
3.4 IMMUNOASSAY MARKET, BY SAMPLE TYPE, 2026 VS. 2031 50
3.5 IMMUNOASSAY MARKET, BY APPLICATION, 2026 VS. 2031 50
3.6 IMMUNOASSAY MARKET, BY END USER, 2026 VS. 2031 51
3.7 IMMUNOASSAY MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES 51

4 MARKET OVERVIEW 52
4.1 INTRODUCTION 52
4.2 MARKET DYNAMICS 53
4.2.1 DRIVERS 53
4.2.1.1 Increasing incidence of chronic and infectious diseases 53
4.2.1.1.1 Increased use of immunoassays in oncology 55
4.2.1.1.2 Rising use of immunoassays in diagnostic applications 56
4.2.1.1.3 High geriatric population 56
4.2.1.2 Increased demand for blood donations in healthcare systems and surgical procedures 57
4.2.1.3 Growth in biotechnology & biopharmaceutical industries 58
4.2.1.4 Increasing adoption of immunoassay-based POC and rapid testing 58
4.2.1.5 Supportive government regulatory policies and initiatives 59
4.2.1.6 Increased consumption of drugs, alcohol, and cannabis 60
4.2.2 RESTRAINTS 60
4.2.2.1 Stringent requirements for approval of immunoassay instruments and consumables 60
4.2.2.2 Technical hurdles of immunoassay kits 61
4.2.3 OPPORTUNITIES 61
4.2.3.1 Increasing growth opportunities in emerging economies 61
4.2.3.2 Focus on importance of companion diagnostics 62
4.2.3.3 Development of condition-specific biomarkers and tests 62
4.2.3.4 Integration of microfluidics in immunoassays 63
4.2.3.5 Improving immunoassay diagnostic technologies 64
4.2.4 CHALLENGES 64
4.2.4.1 Design challenges and low quality of antibodies 64
4.2.4.2 Dearth of skilled professionals 64
4.3 UNMET NEEDS & WHITE SPACES 65
4.3.1 UNMET NEEDS IN IMMUNOASSAY MARKET 65
4.3.2 WHITE SPACE OPPORTUNITIES 66
4.4 INTERCONNECTED MARKETS & CROSS-SECTOR OPPORTUNITIES 67
4.4.1 INTERCONNECTED MARKETS 67
4.4.2 CROSS-SECTOR OPPORTUNITIES 68
4.5 STRATEGIC MOVES BY TIER 1/2/3 PLAYERS 69
4.5.1 KEY MOVES AND STRATEGIC FOCUS 69

5 INDUSTRY TRENDS 71
5.1 PORTER’S FIVE FORCES ANALYSIS 71
5.1.1 INTENSITY OF COMPETITIVE RIVALRY 72
5.1.2 BARGAINING POWER OF SUPPLIERS 72
5.1.3 BARGAINING POWER OF BUYERS 72
5.1.4 THREAT OF SUBSTITUTES 72
5.1.5 THREAT OF NEW ENTRANTS 72
5.2 MACROECONOMIC INDICATORS 72
5.2.1 INTRODUCTION 72
5.2.2 GDP TRENDS & FORECAST 73
5.3 SUPPLY CHAIN ANALYSIS 75
5.4 VALUE CHAIN ANALYSIS 77
5.5 ECOSYSTEM ANALYSIS 78
5.6 PRICING ANALYSIS 79
5.6.1 AVERAGE SELLING PRICE TREND OF IMMUNOASSAY PRODUCTS,
BY KEY PLAYER, 2024–2026 79
5.6.2 AVERAGE SELLING PRICE TREND OF IMMUNOASSAY ANALYZERS,
BY REGION, 2024–2026 81
5.6.3 AVERAGE SELLING PRICE TREND OF IMMUNOASSAY PRODUCTS,
BY TYPE, 2024–2026 81
5.7 TRADE ANALYSIS 83
5.7.1 IMPORT SCENARIO (HS CODE 382200) 83
5.7.2 EXPORT SCENARIO (HS CODE 382200) 84
5.8 KEY CONFERENCES & EVENTS, 2026–2027 84
5.9 TRENDS/DISRUPTIONS IMPACTING CUSTOMERS’ BUSINESSES 85
5.10 INVESTMENT & FUNDING SCENARIO 86
5.11 IMPACT OF 2025 US TARIFFS ON IMMUNOASSAY MARKET 86
5.11.1 INTRODUCTION 86
5.11.2 KEY TARIFF RATES 87
5.11.3 PRICE IMPACT ANALYSIS 87
5.11.4 IMPACT ON COUNTRY/REGION 88
5.11.4.1 North America 88
5.11.4.1.1 US 88
5.11.4.2 Europe 88
5.11.4.2.1 Germany 88
5.11.4.2.2 UK and France 88
5.11.4.3 Asia Pacific 88
5.11.4.3.1 China 89
5.11.4.3.2 Japan 89
5.11.4.3.3 India 89
5.11.5 IMPACT ON END-USE INDUSTRIES 89
5.11.5.1 Hospitals & clinics 89
5.11.5.2 Clinical laboratories 89
5.11.5.3 Blood banks 90
5.11.5.4 Home care settings 90

6 TECHNOLOGICAL ADVANCEMENTS, AI-DRIVEN IMPACT, PATENTS, INNOVATIONS, AND FUTURE APPLICATIONS 91
6.1 KEY EMERGING TECHNOLOGIES 91
6.1.1 ELISA 91
6.2 COMPLEMENTARY TECHNOLOGIES 91
6.2.1 LATERAL FLOW ASSAYS 91
6.3 ADJACENT TECHNOLOGIES 91
6.3.1 MICROFLUIDICS & MINIATURIZED PLATFORMS 91
6.4 TECHNOLOGY/PRODUCT ROADMAP 91
6.5 PATENT ANALYSIS 93
6.5.1 LIST OF MAJOR PATENTS 94
6.6 FUTURE APPLICATIONS 94
6.7 IMPACT OF AI/GEN AI ON IMMUNOASSAY MARKET 95
6.7.1 MARKET POTENTIAL FOR IMMUNOASSAY PRODUCTS 96
6.7.2 TOP USE CASES & MARKET POTENTIAL 96
6.7.3 KEY COMPANIES IMPLEMENTING AI 97
6.7.4 FUTURE OF AI 97

7 SUSTAINABILITY & REGULATORY LANDSCAPE 98
7.1 REGIONAL REGULATIONS & COMPLIANCE 98
7.1.1 REGULATORY LANDSCAPE 98
7.1.1.1 North America 98
7.1.1.1.1 US 98
7.1.1.1.2 Canada 100
7.1.1.2 Europe 101
7.1.1.2.1 Russia 101
7.1.1.3 Asia Pacific 102
7.1.1.3.1 Japan 102
7.1.1.3.2 China 103
7.1.1.3.3 India 103
7.1.1.3.4 Indonesia 104
7.1.1.3.5 South Korea 105
7.1.1.4 Middle East 105
7.1.1.4.1 Saudi Arabia 105
7.1.1.5 Latin America 106
7.1.1.5.1 Mexico 106
7.1.1.5.2 Brazil 107
7.1.1.6 Africa 108
7.1.2 REGULATORY BODIES, GOVERNMENT AGENCIES, AND
OTHER ORGANIZATIONS 108
7.2 SUSTAINABILITY INITIATIVES 110
7.2.1 ENVIRONMENTAL IMPACT & ECO-FRIENDLY INITIATIVES
IN IMMUNOASSAY MARKET 110
7.2.1.1 Eco-friendly Initiatives 110
7.3 SUSTAINABILITY IMPACT & REGULATORY POLICY INITIATIVES 111

8 CUSTOMER LANDSCAPE & BUYER BEHAVIOR 113
8.1 DECISION-MAKING PROCESS 113
8.2 BUYER STAKEHOLDERS & BUYING EVALUATION CRITERIA 113
8.2.1 KEY STAKEHOLDERS IN BUYING PROCESS 113
8.2.2 BUYING CRITERIA 114
8.3 ADOPTION BARRIERS & INTERNAL CHALLENGES 114
8.4 UNMET NEEDS IN VARIOUS END-USE INDUSTRIES 116
8.5 MARKET PROFITABILITY 116
8.5.1 REVENUE POTENTIAL 117
8.5.2 COST DYNAMICS 117
8.5.3 MARGIN OPPORTUNITIES IN KEY APPLICATIONS 117

9 IMMUNOASSAY MARKET, BY PRODUCT 118
9.1 INTRODUCTION 119
9.2 REAGENTS & KITS 119
9.2.1 ELISA REAGENTS & KITS 124
9.2.1.1 Increased use of high-throughput screening in drug discovery programs to drive segment 124
9.2.2 RAPID TEST REAGENTS & KITS 127
9.2.2.1 High demand for preliminary screening tests in remote areas to propel segment growth 127
9.2.3 CLIA REAGENTS & KITS 130
9.2.3.1 Better diagnosis and higher specificity to augment segment growth 130
9.2.4 IFA REAGENTS & KITS 133
9.2.4.1 Better adaptability in clinical diagnostics to support segment growth 133
9.2.5 WESTERN BLOT REAGENTS & KITS 136
9.2.5.1 Western blot reagents & kits to be considered gold standard for infectious disease test result validation 136
9.2.6 OTHER REAGENTS & KITS 139
9.3 ANALYZERS 141
9.3.1 IMMUNOASSAY ANALYZERS MARKET, BY TYPE 145
9.3.1.1 Open-ended systems 146
9.3.1.1.1 Better flexibility and wider availability to drive segment growth 146
9.3.1.2 Closed-ended systems 149
9.3.1.2.1 Higher precision and better automation to fuel segment growth 149
9.3.2 IMMUNOASSAY ANALYZERS MARKET, BY PURCHASE MODE 151
9.3.2.1 Rental purchase 152
9.3.2.1.1 Increased convenience and reduced liability to boost segment growth 152
9.3.2.2 Outright purchase 155
9.3.2.2.1 Inflated cost of immunoassay testing technologies to limit market growth 155

10 IMMUNOASSAY MARKET, BY TECHNOLOGY 158
10.1 INTRODUCTION 159
10.2 ELISA 159
10.2.1 BETTER SENSITIVITY AND QUICKER RESULTS TO DRIVE MARKET 159
10.3 CLIA 163
10.3.1 GOOD SPECIFICITY, WIDE LINEAR RANGE, AND HIGH SENSITIVITY TO AID MARKET GROWTH 163
10.4 IFA 166
10.4.1 GROWING USE OF IFA TO DIAGNOSE ANTIBODIES AND ANALYZE SMALL BIOLOGICAL AND NON-BIOLOGICAL MOLECULES TO BOOST GROWTH 166
10.5 RAPID TESTS 169
10.5.1 FASTER RESULTS AND EASE OF USE TO DRIVE ADOPTION IN POINT-OF-CARE DIAGNOSIS AND EMERGENCY CARE SETTINGS 169
10.6 WESTERN BLOTTING 172
10.6.1 ABILITY TO DETECT AND CONFIRM ANTIBODIES OF RETROVIRUSES
TO SPUR MARKET GROWTH 172
10.7 OTHER TECHNOLOGIES 175

11 IMMUNOASSAY MARKET, BY SPECIMEN 179
11.1 INTRODUCTION 180
11.2 BLOOD 180
11.2.1 HIGH RELIABILITY AND INCREASED NEED DURING SURGICAL
PROCEDURES TO AID MARKET GROWTH 180
11.3 SALIVA 184
11.3.1 ADVANCEMENTS IN IMMUNOASSAY-BASED SALIVA TESTS
TO AUGMENT MARKET GROWTH 184
11.4 URINE 187
11.4.1 INCREASING USE BY LAW ENFORCEMENT AGENCIES AND RISING PREVALENCE OF KIDNEY DISEASES TO FAVOR MARKET GROWTH 187
11.5 OTHER SPECIMENS 190

12 IMMUNOASSAY MARKET, BY APPLICATION 193
12.1 INTRODUCTION 194
12.2 INFECTIOUS DISEASES 194
12.2.1 RISING PREVALENCE OF CHRONIC INFECTIOUS DISEASES TO DRIVE MARKET 194
12.3 ENDOCRINOLOGY 198
12.3.1 RISING INCIDENCE OF DIABETES TO AUGMENT MARKET GROWTH 198
12.4 CARDIOLOGY 201
12.4.1 HIGH BURDEN OF CARDIOVASCULAR DISEASES TO SUPPORT MARKET GROWTH 201
12.5 AUTOIMMUNE DISORDERS 205
12.5.1 HIGH INCIDENCE AND PREVALENCE OF AUTOIMMUNE DISEASES TO AUGMENT MARKET GROWTH 205
12.6 ALLERGY DIAGNOSTICS 208
12.6.1 GROWING PREVALENCE OF ALLERGIES TO AID MARKET GROWTH 208
12.7 ONCOLOGY 211
12.7.1 RISING BURDEN OF CANCER AND GROWING EMPHASIS ON EARLY DETECTION TO PROPEL MARKET GROWTH 211
12.8 BONE & MINERAL DISORDERS 214
12.8.1 INCREASING PREVALENCE OF OSTEOPOROSIS, VITAMIN D DEFICIENCY, AND ARTHRITIS TO AID MARKET GROWTH 214
12.9 DRUG MONITORING & TESTING 218
12.9.1 RISING DRUG ABUSE AND INCREASING ILLICIT DRUG CONSUMPTION TO ACCELERATE MARKET GROWTH 218
12.10 BLOOD SCREENING 221
12.10.1 RISING EMPHASIS ON BLOOD DONATIONS TO FAVOR MARKET GROWTH 221
12.11 NEWBORN SCREENING 224
12.11.1 TECHNOLOGICAL ADVANCEMENTS AND FAVORABLE GOVERNMENT INITIATIVES TO PROPEL MARKET GROWTH 224
12.12 OTHER APPLICATIONS 227

13 IMMUNOASSAY MARKET, BY END USER 231
13.1 INTRODUCTION 232
13.2 HOSPITALS & CLINICS 232
13.2.1 GROWING PATIENT POPULATION AND RISING TESTING VOLUMES
TO DRIVE MARKET 232
13.3 CLINICAL LABORATORIES 236
13.3.1 INCREASING NUMBER OF ACCREDITED LABORATORIES TO DRIVE MARKET 236
13.4 HOME CARE SETTINGS 239
13.4.1 RISING UTILIZATION OF POC DIAGNOSTICS AND AT-HOME ANTIGEN DIAGNOSIS TO PROPEL MARKET GROWTH 239
13.5 BLOOD BANKS 242
13.5.1 INCREASING NUMBER OF ACCIDENTS AND RISING DEMAND FOR BLOOD DURING SURGERIES TO SPUR MARKET GROWTH 242

14 IMMUNOASSAY MARKET, BY REGION 246
14.1 INTRODUCTION 247
14.2 NORTH AMERICA 247
14.2.1 US 253
14.2.1.1 US to dominate North American immunoassay market during forecast period 253
14.2.2 CANADA 259
14.2.2.1 Increasing government support and rising incidence of chronic diseases to augment market growth 259
14.3 EUROPE 264
14.3.1 GERMANY 269
14.3.1.1 High healthcare spending and favorable government initiatives to propel market growth 269
14.3.2 ITALY 273
14.3.2.1 Rising geriatric population and increasing cancer prevalence to spur market growth 273
14.3.3 FRANCE 278
14.3.3.1 Increased use of POC testing and favorable reimbursement policies to boost market growth 278
14.3.4 UK 282
14.3.4.1 Government support for disease diagnostics and favorable investment scenario to drive market 282
14.3.5 SPAIN 287
14.3.5.1 Increasing adoption of technologically advanced immunoassay systems to augment market growth 287
14.3.6 RUSSIA 292
14.3.6.1 Increasing access to quality healthcare and developing pharmaceutical industry to favor market growth 292
14.3.7 REST OF EUROPE 296
14.4 ASIA PACIFIC 301
14.4.1 CHINA 307
14.4.1.1 Increasing government investments and rising geriatric population to accelerate market growth 307
14.4.2 JAPAN 311
14.4.2.1 Increasing investments in healthcare technologies and research activities to fuel market growth 311
14.4.3 INDIA 316
14.4.3.1 Growing medical tourism and improving healthcare infrastructure to propel market growth 316
14.4.4 AUSTRALIA 320
14.4.4.1 Increasing incidence of cancer and rising focus on blood donations to favor market growth 320
14.4.5 SOUTH KOREA 325
14.4.5.1 Rising healthcare spending and increasing research investments to fuel market growth 325
14.4.6 INDONESIA 329
14.4.6.1 High geriatric population and favorable government healthcare policies to accelerate market growth 329
14.4.7 REST OF ASIA PACIFIC 334
14.5 LATIN AMERICA 338
14.5.1 BRAZIL 343
14.5.1.1 Growing geriatric population and government investments to accelerate market growth 343
14.5.2 MEXICO 347
14.5.2.1 Increasing geriatric population and rising popularity of medical tourism to propel market growth 347
14.5.3 REST OF LATIN AMERICA 352
14.6 MIDDLE EAST & AFRICA 356
14.6.1 LACK OF SKILLED LABORATORY PERSONNEL AND UNFAVORABLE REIMBURSEMENT POLICIES TO LIMIT MARKET GROWTH 356

15 IMMUNOASSAYS MARKET: VOLUME ANALYSIS 361
15.1 INTRODUCTION 361
15.2 US: NUMBER OF IN VITRO DIAGNOSTICS TESTS CONDUCTED,
2024–2031 (BILLION UNITS) 361

16 COMPETITIVE LANDSCAPE 362
16.1 INTRODUCTION 362
16.2 KEY PLAYER STRATEGIES/RIGHT TO WIN 362
16.2.1 OVERVIEW OF STRATEGIES DEPLOYED BY PLAYERS
IN IMMUNOASSAY MARKET 363
16.3 REVENUE ANALYSIS, 2023–2025 364
16.4 MARKET SHARE ANALYSIS, 2025 365
16.4.1 GLOBAL MARKET SHARE ANALYSIS, 2025 365
16.5 COMPANY EVALUATION MATRIX: KEY PLAYERS, 2025 366
16.5.1 STARS 366
16.5.2 EMERGING LEADERS 367
16.5.3 PERVASIVE PLAYERS 367
16.5.4 PARTICIPANTS 367
16.5.5 COMPANY FOOTPRINT: KEY PLAYERS, 2025 368
16.5.5.1 Company footprint 368
16.5.5.2 Region footprint 369
16.5.5.3 Product footprint 370
16.5.5.4 Specimen footprint 371
16.6 COMPANY EVALUATION MATRIX: STARTUPS/SMES, 2025 372
16.6.1 PROGRESSIVE COMPANIES 372
16.6.2 RESPONSIVE COMPANIES 372
16.6.3 DYNAMIC COMPANIES 372
16.6.4 STARTING BLOCKS 372
16.6.5 COMPETITIVE BENCHMARKING: STARTUPS/SMES, 2025 374
16.6.5.1 List of key startups/SMEs 374
16.6.5.2 Competitive benchmarking of key startups/SMEs 375
16.7 COMPANY VALUATION & FINANCIAL METRICS 376
16.7.1 FINANCIAL METRICS 376
16.7.2 COMPANY VALUATION 376
16.8 BRAND/PRODUCT COMPARISON 377
16.9 COMPETITIVE SCENARIO 378
16.9.1 PRODUCT LAUNCHES & APPROVALS 378
16.9.2 DEALS 378
16.9.3 EXPANSIONS 379

17 COMPANY PROFILES 380
17.1 KEY PLAYERS 380
17.1.1 ABBOTT 380
17.1.1.1 Business overview 380
17.1.1.2 Products offered 381
17.1.1.3 Recent developments 382
17.1.1.3.1 Product launches & approvals 382
17.1.1.3.2 Deals 384
17.1.1.3.3 Expansions 384
17.1.1.4 MnM view 385
17.1.1.4.1 Right to win 385
17.1.1.4.2 Strategic choices 385
17.1.1.4.3 Weaknesses & competitive threats 385
17.1.2 F. HOFFMANN-LA ROCHE LTD. 386
17.1.2.1 Business overview 386
17.1.2.2 Products offered 387
17.1.2.3 Recent developments 389
17.1.2.3.1 Product launches & approvals 389
17.1.2.3.2 Deals 390
17.1.2.3.3 Expansions 390
17.1.2.4 MnM view 391
17.1.2.4.1 Right to win 391
17.1.2.4.2 Strategic choices 391
17.1.2.4.3 Weaknesses & competitive threats 391
17.1.3 SIEMENS HEALTHINEERS AG 392
17.1.3.1 Business overview 392
17.1.3.2 Products offered 393
17.1.3.3 Recent developments 394
17.1.3.3.1 Product launches & approvals 394
17.1.3.3.2 Deals 394
17.1.3.3.3 Expansions 396
17.1.3.4 MnM view 396
17.1.3.4.1 Right to win 396
17.1.3.4.2 Strategic choices 396
17.1.3.4.3 Weaknesses & competitive threats 396
17.1.4 DANAHER CORPORATION 397
17.1.4.1 Business overview 397
17.1.4.2 Products offered 398
17.1.4.3 Recent developments 399
17.1.4.3.1 Product launches & approvals 399
17.1.4.3.2 Deals 401
17.1.4.3.3 Expansions 402
17.1.4.4 MnM view 402
17.1.4.4.1 Right to win 402
17.1.4.4.2 Strategic choices 403
17.1.4.4.3 Weaknesses & competitive threats 403
17.1.5 THERMO FISHER SCIENTIFIC INC. 404
17.1.5.1 Business overview 404
17.1.5.2 Products offered 406
17.1.5.3 Recent developments 407
17.1.5.3.1 Product launches & approvals 407
17.1.5.3.2 Deals 407
17.1.5.4 MnM view 408
17.1.5.4.1 Right to win 408
17.1.5.4.2 Strategic choices 408
17.1.5.4.3 Weaknesses & competitive threats 408
17.1.6 REVVITY INC. 409
17.1.6.1 Business overview 409
17.1.6.2 Products offered 410
17.1.6.3 Recent developments 411
17.1.6.3.1 Product launches & approvals 411
17.1.6.3.2 Other developments 411
17.1.7 WATERS CORPORATION 412
17.1.7.1 Business overview 412
17.1.7.2 Products offered 413
17.1.7.3 Recent developments 414
17.1.7.3.1 Deals 414
17.1.8 DIASORIN S.P.A. 415
17.1.8.1 Business overview 415
17.1.8.2 Products offered 416
17.1.8.3 Recent developments 418
17.1.8.3.1 Product launches & approvals 418
17.1.8.3.2 Deals 419
17.1.9 BIO-RAD LABORATORIES, INC. 420
17.1.9.1 Business overview 420
17.1.9.2 Products offered 421
17.1.9.3 Recent developments 423
17.1.9.3.1 Product launches 423
17.1.9.3.2 Deals 423
17.1.10 QUIDELORTHO CORPORATION 424
17.1.10.1 Business overview 424
17.1.10.2 Products offered 426
17.1.10.3 Recent developments 428
17.1.10.3.1 Product launches & approvals 428
17.1.10.3.2 Expansions 428
17.1.11 BIOMÉRIEUX 429
17.1.11.1 Business overview 429
17.1.11.2 Products offered 430
17.1.11.3 Recent developments 431
17.1.11.3.1 Product launches & approvals 431
17.1.11.3.2 Deals 432
17.1.12 QIAGEN 433
17.1.12.1 Business overview 433
17.1.12.2 Products offered 434
17.1.12.3 Recent developments 435
17.1.12.3.1 Deals 435
17.1.13 SYSMEX CORPORATION 436
17.1.13.1 Business overview 436
17.1.13.2 Products offered 438
17.1.13.3 Recent developments 438
17.1.13.3.1 Product launches 438
17.1.13.3.2 Deals 439
17.1.13.3.3 Expansions 440
17.1.14 AGILENT TECHNOLOGIES, INC. 441
17.1.14.1 Business overview 441
17.1.14.2 Products offered 442
17.1.14.3 Recent developments 443
17.1.14.3.1 Product approvals 443
17.1.14.3.2 Deals 443
17.1.15 SHENZHEN MINDRAY BIO-MEDICAL ELECTRONICS CO., LTD. 444
17.1.15.1 Business overview 444
17.1.15.2 Products offered 445
17.1.15.3 Recent developments 445
17.1.15.3.1 Product launches 445
17.2 OTHER PLAYERS 446
17.2.1 MERCK KGAA 446
17.2.2 MERIDIAN BIOSCIENCE 447
17.2.3 BIO-TECHNE 448
17.2.4 CELLABS 449
17.2.5 ABNOVA CORPORATION 450
17.2.6 J. MITRA & CO. PVT. LTD. 450
17.2.7 TOSOH CORPORATION (TOSOH BIOSCIENCES) 451
17.2.8 CELL SCIENCES 451
17.2.9 ENZO BIOCHEM INC. 452
17.2.10 CREATIVE DIAGNOSTICS 453
17.2.11 BOSTER BIOLOGICAL TECHNOLOGY 453
17.2.12 ELABSCIENCE BIONOVATION INC. 454
17.2.13 WAK-CHEMIE MEDICAL GMBH 454
17.2.14 SERA CARE 455
17.2.15 EPITOPE DIAGNOSTICS, INC. 455
17.2.16 KAMIYA BIOMEDICAL COMPANY 456
17.2.17 GYROS PROTEIN TECHNOLOGIES AB 456
17.2.18 TRIVITRON HEALTHCARE 457
17.2.19 INBIOS INTERNATIONAL, INC. 457
17.2.20 MACCURA BIOTECHNOLOGY CO., LTD. 458

18 RESEARCH METHODOLOGY 459
18.1 RESEARCH DATA 459
18.1.1 SECONDARY RESEARCH 460
18.1.1.1 Key secondary sources 460
18.1.1.2 Key data from secondary sources 461
18.1.2 PRIMARY RESEARCH 461
18.1.2.1 Key primary sources 461
18.1.2.2 Key objectives of primary research 462
18.1.2.3 Key data from primary sources 462
18.1.2.4 Key industry insights 464
18.2 MARKET SIZE ESTIMATION 465
18.2.1 BOTTOM-UP APPROACH 465
18.2.2 COMPANY PRESENTATIONS & PRIMARY INTERVIEWS 466
18.2.3 TOP-DOWN APPROACH 468
18.3 DATA TRIANGULATION 469
18.4 MARKET SHARE ANALYSIS 470
18.5 STUDY ASSUMPTIONS 470
18.5.1 MARKET ASSUMPTIONS 470
18.5.2 GROWTH RATE ASSUMPTIONS 470
18.6 RESEARCH LIMITATIONS 471
18.6.1 METHODOLOGY-RELATED LIMITATIONS 471
18.6.2 SCOPE-RELATED LIMITATIONS 471
18.7 RISK ANALYSIS 471

19 APPENDIX 472
19.1 DISCUSSION GUIDE 472
19.2 KNOWLEDGESTORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL 476
19.3 CUSTOMIZATION OPTIONS 478
19.4 RELATED REPORTS 479
19.5 AUTHOR DETAILS 480

ページTOPに戻る



List of Tables/Graphs

FIGURE 1 IMMUNOASSAY MARKET SEGMENTATION & REGIONAL SCOPE 39.
FIGURE 2 IMMUNOASSAY MARKET: YEARS CONSIDERED 41.
FIGURE 3 KEY INSIGHTS & MARKET HIGHLIGHTS 43.
FIGURE 4 GLOBAL IMMUNOASSAY MARKET, 2024–2031 44.
FIGURE 5 MAJOR STRATEGIES ADOPTED BY KEY PLAYERS IN IMMUNOASSAY MARKET, 2024–2026 44.
FIGURE 6 DISRUPTIVE TRENDS IMPACTING GROWTH OF IMMUNOASSAY MARKET 45.
FIGURE 7 HIGH-GROWTH SEGMENTS & EMERGING FRONTIERS IN.
IMMUNOASSAY MARKET, 2025 46.
FIGURE 8 ASIA PACIFIC TO REGISTER HIGHEST GROWTH DURING FORECAST PERIOD 47.
FIGURE 9 HIGH PREVALENCE OF CHRONIC AND INFECTIOUS DISEASES TO DRIVE MARKET 48.
FIGURE 10 REAGENTS & KITS SEGMENT TO DOMINATE MARKET DURING FORECAST PERIOD 49.
FIGURE 11 CLIA SEGMENT TO LEAD MARKET DURING FORECAST PERIOD 49.
FIGURE 12 BLOOD SAMPLES SEGMENT TO LEAD MARKET DURING FORECAST PERIOD 50.
FIGURE 13 INFECTIOUS DISEASES SEGMENT TO LEAD MARKET DURING FORECAST PERIOD 50.
FIGURE 14 HOSPITALS & CLINICS SEGMENT TO COMMAND LARGEST.
SHARE DURING FORECAST PERIOD 51.
FIGURE 15 ASIA PACIFIC TO REGISTER HIGHEST GROWTH DURING FORECAST PERIOD 51.
FIGURE 16 IMMUNOASSAY MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES,.
AND CHALLENGES 53.
FIGURE 17 IMMUNOASSAY MARKET: PORTER’S FIVE FORCES ANALYSIS 71.
FIGURE 18 IMMUNOASSAY MARKET: SUPPLY CHAIN ANALYSIS 76.
FIGURE 19 IMMUNOASSAY MARKET: VALUE CHAIN ANALYSIS 77.
FIGURE 20 IMMUNOASSAY MARKET: ECOSYSTEM ANALYSIS 78.
FIGURE 21 IMMUNOASSAY MARKET: TRENDS/DISRUPTIONS IMPACTING.
CUSTOMERS’ BUSINESSES 85.
FIGURE 22 NUMBER OF DEALS & FUNDING ACTIVITIES IN IMMUNOASSAY MARKET 86.
FIGURE 23 TOP 10 PATENT OWNERS/APPLICANTS IN IMMUNOASSAY MARKET,.
JANUARY 2015–DECEMBER 2024 93.
FIGURE 24 MARKET POTENTIAL OF AI IN IMMUNOASSAY MARKET 96.
FIGURE 25 US: REGULATORY PROCESS FOR IN VITRO DIAGNOSTIC DEVICES 99.
FIGURE 26 CANADA: REGULATORY PROCESS FOR IN VITRO DIAGNOSTIC DEVICES 100.
FIGURE 27 JAPAN: REGULATORY PROCESS FOR IN VITRO DIAGNOSTIC DEVICES 102.
FIGURE 28 INDIA: REGULATORY PROCESS FOR IN VITRO DIAGNOSTIC DEVICES 104.
FIGURE 29 MEXICO: REGULATORY PROCESS FOR IN VITRO DIAGNOSTIC DEVICES 106.
FIGURE 30 BRAZIL: REGULATORY PROCESS FOR IN VITRO DIAGNOSTIC DEVICES 108.
FIGURE 31 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS, BY END USER 113.
FIGURE 32 KEY BUYING CRITERIA, BY END USER 114.
FIGURE 33 NORTH AMERICA: IMMUNOASSAY MARKET SNAPSHOT 248.
FIGURE 34 ASIA PACIFIC: IMMUNOASSAY MARKET SNAPSHOT 302.
FIGURE 35 REVENUE ANALYSIS OF KEY PLAYERS IN IMMUNOASSAY MARKET,.
2023–2025 (USD MILLION) 364.
FIGURE 36 IMMUNOASSAY MARKET SHARE ANALYSIS, 2025 (GLOBAL) 365.
FIGURE 37 IMMUNOASSAY MARKET: COMPANY EVALUATION MATRIX (KEY PLAYERS), 2025 367.
FIGURE 38 IMMUNOASSAY MARKET: COMPANY FOOTPRINT 368.
FIGURE 39 IMMUNOASSAY MARKET: COMPANY EVALUATION MATRIX.
(STARTUPS/SMES), 2025 373.
FIGURE 40 EV/EBITDA OF KEY VENDORS 376.
FIGURE 41 YEAR-TO-DATE (YTD) PRICE TOTAL RETURN AND 5-YEAR STOCK BETA.
OF KEY VENDORS 376.
FIGURE 42 IMMUNOASSAY MARKET: BRAND/PRODUCT COMPARISON 377.
FIGURE 43 ABBOTT: COMPANY SNAPSHOT (2025) 381.
FIGURE 44 F. HOFFMANN-LA ROCHE LTD.: COMPANY SNAPSHOT (2025) 387.
FIGURE 45 SIEMENS HEALTHINEERS AG: COMPANY SNAPSHOT (2025) 393.
FIGURE 46 DANAHER CORPORATION: COMPANY SNAPSHOT (2025) 398.
FIGURE 47 THERMO FISHER SCIENTIFIC INC.: COMPANY SNAPSHOT (2025) 405.
FIGURE 48 REVVITY INC.: COMPANY SNAPSHOT (2025) 410.
FIGURE 49 WATERS CORPORATION: COMPANY SNAPSHOT (2025) 413.
FIGURE 50 DIASORIN S.P.A.: COMPANY SNAPSHOT (2025) 416.
FIGURE 51 BIO-RAD LABORATORIES, INC.: COMPANY SNAPSHOT (2025) 421.
FIGURE 52 QUIDELORTHO CORPORATION: COMPANY SNAPSHOT (2025) 425.
FIGURE 53 BIOMÉRIEUX: COMPANY SNAPSHOT (2025) 430.
FIGURE 54 QIAGEN: COMPANY SNAPSHOT (2025) 434.
FIGURE 55 SYSMEX CORPORATION: COMPANY SNAPSHOT (2025) 437.
FIGURE 56 AGILENT TECHNOLOGIES, INC.: COMPANY SNAPSHOT (2025) 442.
FIGURE 57 SHENZHEN MINDRAY BIO-MEDICAL ELECTRONICS CO., LTD.:.
COMPANY SNAPSHOT (2025) 444.
FIGURE 58 IMMUNOASSAY MARKET: RESEARCH DESIGN 459.
FIGURE 59 IMMUNOASSAY MARKET: KEY DATA FROM SECONDARY SOURCES 461.
FIGURE 60 IMMUNOASSAY MARKET: KEY PRIMARY SOURCES 461.
FIGURE 61 IMMUNOASSAY MARKET: KEY INSIGHTS FROM INDUSTRY EXPERTS 464.
FIGURE 62 BREAKDOWN OF PRIMARY INTERVIEWS: SUPPLY- AND.
DEMAND-SIDE PARTICIPANTS 464.
FIGURE 63 BREAKDOWN OF PRIMARY INTERVIEWS: BY COMPANY TYPE,.
DESIGNATION, AND REGION 465.
FIGURE 64 IMMUNOASSAY MARKET: COMPANY REVENUE ESTIMATION.
(REVENUE SHARE ANALYSIS) 466.
FIGURE 65 IMMUNOASSAY MARKET: CAGR PROJECTIONS (SUPPLY-SIDE ANALYSIS) 467.
FIGURE 66 IMMUNOASSAY MARKET: TOP-DOWN APPROACH 468.
FIGURE 67 IMMUNOASSAY MARKET: DATA TRIANGULATION METHODOLOGY 469.
TABLE 1 IMMUNOASSAY MARKET: INCLUSIONS & EXCLUSIONS 40.
TABLE 2 INCREASING INCIDENCE OF CANCER, BY REGION, 2024 VS. 2040 (MILLION) 55.
TABLE 3 NUMBER OF NEW CANCER CASES, BY CANCER TYPE, 2024 55.
TABLE 4 DETECTION TIME OF DRUG OR DRUG CLASS IN URINE TESTING 56.
TABLE 5 NEW TESTS LAUNCHED BY KEY PLAYERS, 2023–2026 63.
TABLE 6 LAB-ON-CHIP IMMUNOASSAYS/DEVICES/SYSTEMS OFFERED BY KEY PLAYERS 63.
TABLE 7 IMMUNOASSAY MARKET: PORTER’S FIVE FORCES 71.
TABLE 8 GDP PERCENTAGE CHANGE (%), BY KEY COUNTRY, 2023–2030 73.
TABLE 9 NORTH AMERICA: MACROECONOMIC INDICATORS 74.
TABLE 10 EUROPE: MACROECONOMIC INDICATORS 74.
TABLE 11 ASIA PACIFIC: MACROECONOMIC INDICATORS 75.
TABLE 12 LATIN AMERICA: MACROECONOMIC INDICATORS 75.
TABLE 13 MIDDLE EAST & AFRICA: MACROECONOMIC INDICATORS 75.
TABLE 14 IMMUNOASSAY MARKET: ROLE OF COMPANIES IN ECOSYSTEM 79.
TABLE 15 AVERAGE SELLING PRICE TREND OF IMMUNOASSAY PRODUCTS,.
BY KEY PLAYER, 2024–2026 (USD) 80.
TABLE 16 AVERAGE SELLING PRICE TREND OF CLINICAL IMMUNOASSAY ANALYZERS,.
BY REGION, 2024–2026 (USD) 81.
TABLE 17 AVERAGE SELLING PRICE TREND OF IMMUNOASSAY PRODUCTS, BY TYPE,.
2024–2026 (USD) 82.
TABLE 18 IMPORT DATA FOR HS CODE 382200-COMPLIANT PRODUCTS, BY COUNTRY, 2021–2025 (USD MILLION) 83.
TABLE 19 EXPORT DATA FOR HS CODE 382200-COMPLIANT PRODUCTS, BY COUNTRY, 2021–2025 (USD MILLION) 84.
TABLE 20 IMMUNOASSAY MARKET: KEY CONFERENCES & EVENTS, 2026–2027 84.
TABLE 21 US-ADJUSTED RECIPROCAL TARIFF RATES 87.
TABLE 22 KEY PATENTS IN IMMUNOASSAY, 2023–2026 94.
TABLE 23 KEY COMPANIES IMPLEMENTING AI IN IMMUNOASSAY MARKET 97.
TABLE 24 US: CLASSIFICATION AND RISK LEVEL OF IMMUNOASSAY PRODUCTS 98.
TABLE 25 EUROPE: CLASSIFICATION AND RISK LEVEL OF IN VITRO DIAGNOSTIC DEVICES 101.
TABLE 26 RUSSIA: CLASSIFICATION AND RISK LEVEL OF IN VITRO DIAGNOSTIC DEVICES 101.
TABLE 27 JAPAN: CLASSIFICATION OF IN VITRO DIAGNOSTIC REAGENTS 102.
TABLE 28 JAPAN: TIME, COST, AND COMPLEXITY OF REGISTRATION PROCESS 103.
TABLE 29 CHINA: TIME, COST, AND COMPLEXITY OF REGISTRATION PROCESS 103.
TABLE 30 INDONESIA: REGISTRATION PROCESS FOR IN VITRO DIAGNOSTIC DEVICES 104.
TABLE 31 SOUTH KOREA: TIME, COST, AND COMPLEXITY OF REGISTRATION PROCESS 105.
TABLE 32 SAUDI ARABIA: TIME, COST, AND COMPLEXITY OF REGISTRATION PROCESS 106.
TABLE 33 MEXICO: TIME, COST, AND COMPLEXITY OF REGISTRATION PROCESS 107.
TABLE 34 NORTH AMERICA: REGULATORY BODIES, GOVERNMENT AGENCIES,.
AND OTHER ORGANIZATIONS 108.
TABLE 35 EUROPE: REGULATORY BODIES, GOVERNMENT AGENCIES,.
AND OTHER ORGANIZATIONS 109.
TABLE 36 ASIA PACIFIC: REGULATORY BODIES, GOVERNMENT AGENCIES,.
AND OTHER ORGANIZATIONS 109.
TABLE 37 LATIN AMERICA: REGULATORY BODIES, GOVERNMENT AGENCIES,.
AND OTHER ORGANIZATIONS 109.
TABLE 38 REST OF THE WORLD: REGULATORY BODIES, GOVERNMENT AGENCIES,.
AND OTHER ORGANIZATIONS 110.
TABLE 39 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS, BY END USER (%) 113.
TABLE 40 KEY BUYING CRITERIA, BY END USER 114.
TABLE 41 ADOPTION BARRIERS & INTERNAL CHALLENGES 115.
TABLE 42 IMMUNOASSAY MARKET: UNMET NEEDS IN VARIOUS END-USE INDUSTRIES 116.
TABLE 43 IMMUNOASSAY MARKET, BY PRODUCT, 2024–2031 (USD MILLION) 119.
TABLE 44 KEY REAGENTS & KITS AVAILABLE IN MARKET 120.
TABLE 45 IMMUNOASSAY REAGENTS & KITS MARKET, BY REGION,.
2024–2031 (USD MILLION) 121.
TABLE 46 IMMUNOASSAY REAGENTS & KITS MARKET, BY TYPE, 2024–2031 (USD MILLION) 121.
TABLE 47 NORTH AMERICA: IMMUNOASSAY REAGENTS & KITS MARKET,.
BY COUNTRY, 2024–2031 (USD MILLION) 122.
TABLE 48 EUROPE: IMMUNOASSAY REAGENTS & KITS MARKET, BY COUNTRY,.
2024–2031 (USD MILLION) 122.
TABLE 49 ASIA PACIFIC: IMMUNOASSAY REAGENTS & KITS MARKET, BY COUNTRY,.
2024–2031 (USD MILLION) 123.
TABLE 50 LATIN AMERICA: IMMUNOASSAY REAGENTS & KITS MARKET, BY COUNTRY,.
2024–2031 (USD MILLION) 123.
TABLE 51 ELISA REAGENTS & KITS MARKET, BY REGION, 2024–2031 (USD MILLION) 125.
TABLE 52 NORTH AMERICA: ELISA REAGENTS & KITS MARKET, BY COUNTRY,.
2024–2031 (USD MILLION) 125.
TABLE 53 EUROPE: ELISA REAGENTS & KITS MARKET, BY COUNTRY,.
2024–2031 (USD MILLION) 126.
TABLE 54 ASIA PACIFIC: ELISA REAGENTS & KITS MARKET, BY COUNTRY,.
2024–2031 (USD MILLION) 126.
TABLE 55 LATIN AMERICA: ELISA REAGENTS & KITS MARKET, BY COUNTRY,.
2024–2031 (USD MILLION) 127.
TABLE 56 RAPID TEST REAGENTS & KITS MARKET, BY REGION, 2024–2031 (USD MILLION) 128.
TABLE 57 NORTH AMERICA: RAPID TEST REAGENTS & KITS MARKET, BY COUNTRY,.
2024–2031 (USD MILLION) 128.
TABLE 58 EUROPE: RAPID TEST REAGENTS & KITS MARKET, BY COUNTRY,.
2024–2031 (USD MILLION) 129.
TABLE 59 ASIA PACIFIC: RAPID TEST REAGENTS & KITS MARKET, BY COUNTRY,.
2024–2031 (USD MILLION) 129.
TABLE 60 LATIN AMERICA: RAPID TEST REAGENTS & KITS MARKET, BY COUNTRY,.
2024–2031 (USD MILLION) 130.
TABLE 61 CLIA REAGENTS & KITS MARKET, BY REGION, 2024–2031 (USD MILLION) 131.
TABLE 62 NORTH AMERICA: CLIA REAGENTS & KITS MARKET, BY COUNTRY,.
2024–2031 (USD MILLION) 131.
TABLE 63 EUROPE: CLIA REAGENTS & KITS MARKET, BY COUNTRY,.
2024–2031 (USD MILLION) 132.
TABLE 64 ASIA PACIFIC: CLIA REAGENTS & KITS MARKET, BY COUNTRY,.
2024–2031 (USD MILLION) 132.
TABLE 65 LATIN AMERICA: CLIA REAGENTS & KITS MARKET, BY COUNTRY,.
2024–2031 (USD MILLION) 133.
TABLE 66 IFA REAGENTS & KITS MARKET, BY REGION, 2024–2031 (USD MILLION) 133.
TABLE 67 NORTH AMERICA: IFA REAGENTS & KITS MARKET, BY COUNTRY,.
2024–2031 (USD MILLION) 134.
TABLE 68 EUROPE: IFA REAGENTS & KITS MARKET, BY COUNTRY,.
2024–2031 (USD MILLION) 134.
TABLE 69 ASIA PACIFIC: IFA REAGENTS & KITS MARKET, BY COUNTRY,.
2024–2031 (USD MILLION) 135.
TABLE 70 LATIN AMERICA: IFA REAGENTS & KITS MARKET, BY COUNTRY,.
2024–2031 (USD MILLION) 135.
TABLE 71 WESTERN BLOT REAGENTS & KITS MARKET, BY REGION,.
2024–2031 (USD MILLION) 136.
TABLE 72 NORTH AMERICA: WESTERN BLOT REAGENTS & KITS MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 137.
TABLE 73 EUROPE: WESTERN BLOT REAGENTS & KITS MARKET, BY COUNTRY,.
2024–2031 (USD MILLION) 137.
TABLE 74 ASIA PACIFIC: WESTERN BLOT REAGENTS & KITS MARKET, BY COUNTRY,.
2024–2031 (USD MILLION) 138.
TABLE 75 LATIN AMERICA: WESTERN BLOT REAGENTS & KITS MARKET, BY COUNTRY,.
2024–2031 (USD MILLION) 138.
TABLE 76 OTHER REAGENTS & KITS MARKET, BY REGION, 2024–2031 (USD MILLION) 139.
TABLE 77 NORTH AMERICA: OTHER REAGENTS & KITS MARKET, BY COUNTRY,.
2024–2031 (USD MILLION) 139.
TABLE 78 EUROPE: OTHER REAGENTS & KITS MARKET, BY COUNTRY,.
2024–2031 (USD MILLION) 140.
TABLE 79 ASIA PACIFIC: OTHER REAGENTS & KITS MARKET, BY COUNTRY,.
2024–2031 (USD MILLION) 140.
TABLE 80 LATIN AMERICA: OTHER REAGENTS & KITS MARKET, BY COUNTRY,.
2024–2031 (USD MILLION) 141.
TABLE 81 KEY ANALYZERS AVAILABLE IN MARKET 142.
TABLE 82 IMMUNOASSAY ANALYZERS MARKET, BY REGION, 2024–2031 (USD MILLION) 143.
TABLE 83 NORTH AMERICA: IMMUNOASSAY ANALYZERS MARKET, BY COUNTRY,.
2024–2031 (USD MILLION) 143.
TABLE 84 EUROPE: IMMUNOASSAY ANALYZERS MARKET, BY COUNTRY,.
2024–2031 (USD MILLION) 144.
TABLE 85 ASIA PACIFIC: IMMUNOASSAY ANALYZERS MARKET, BY COUNTRY,.
2024–2031 (USD MILLION) 144.
TABLE 86 LATIN AMERICA: IMMUNOASSAY ANALYZERS MARKET, BY COUNTRY,.
2024–2031 (USD MILLION) 145.
TABLE 87 IMMUNOASSAY ANALYZERS MARKET, BY TYPE, 2024–2031 (USD MILLION) 146.
TABLE 88 OPEN-ENDED IMMUNOASSAY SYSTEMS MARKET, BY REGION,.
2024–2031 (USD MILLION) 146.
TABLE 89 NORTH AMERICA: OPEN-ENDED IMMUNOASSAY SYSTEMS MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 147.
TABLE 90 EUROPE: OPEN-ENDED IMMUNOASSAY SYSTEMS MARKET, BY COUNTRY,.
2024–2031 (USD MILLION) 147.
TABLE 91 ASIA PACIFIC: OPEN-ENDED IMMUNOASSAY SYSTEMS MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 148.
TABLE 92 LATIN AMERICA: OPEN-ENDED IMMUNOASSAY SYSTEMS MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 148.
TABLE 93 CLOSED-ENDED IMMUNOASSAY SYSTEMS MARKET, BY REGION,.
2024–2031 (USD MILLION) 149.
TABLE 94 NORTH AMERICA: CLOSED-ENDED IMMUNOASSAY SYSTEMS MARKET,.
BY COUNTRY, 2024–2031 (USD MILLION) 149.
TABLE 95 EUROPE: CLOSED-ENDED IMMUNOASSAY SYSTEMS MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 150.
TABLE 96 ASIA PACIFIC: CLOSED-ENDED IMMUNOASSAY SYSTEMS MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 150.
TABLE 97 LATIN AMERICA: CLOSED-ENDED IMMUNOASSAY SYSTEMS MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 151.
TABLE 98 IMMUNOASSAY ANALYZERS MARKET, BY PURCHASE MODE,.
2024–2031 (USD MILLION) 151.
TABLE 99 IMMUNOASSAY ANALYZERS MARKET FOR RENTAL PURCHASE, BY REGION,.
2024–2031 (USD MILLION) 152.
TABLE 100 NORTH AMERICA: IMMUNOASSAY ANALYZERS MARKET FOR RENTAL PURCHASE, BY COUNTRY, 2024–2031 (USD MILLION) 153.
TABLE 101 EUROPE: IMMUNOASSAY ANALYZERS MARKET FOR RENTAL PURCHASE,.
BY COUNTRY, 2024–2031 (USD MILLION) 153.
TABLE 102 ASIA PACIFIC: IMMUNOASSAY ANALYZERS MARKET FOR RENTAL PURCHASE,.
BY COUNTRY, 2024–2031 (USD MILLION) 154.
TABLE 103 LATIN AMERICA: IMMUNOASSAY ANALYZERS MARKET FOR RENTAL PURCHASE,.
BY COUNTRY, 2024–2031 (USD MILLION) 154.
TABLE 104 IMMUNOASSAY ANALYZERS MARKET FOR OUTRIGHT PURCHASE, BY REGION, 2024–2031 (USD MILLION) 155.
TABLE 105 NORTH AMERICA: IMMUNOASSAY ANALYZERS MARKET FOR OUTRIGHT PURCHASE, BY COUNTRY, 2024–2031 (USD MILLION) 155.
TABLE 106 EUROPE: IMMUNOASSAY ANALYZERS MARKET FOR OUTRIGHT PURCHASE,.
BY COUNTRY, 2024–2031 (USD MILLION) 156.
TABLE 107 ASIA PACIFIC: IMMUNOASSAY ANALYZERS MARKET FOR OUTRIGHT PURCHASE,.
BY COUNTRY, 2024–2031 (USD MILLION) 156.
TABLE 108 LATIN AMERICA: IMMUNOASSAY ANALYZERS MARKET FOR OUTRIGHT PURCHASE, BY COUNTRY, 2024–2031 (USD MILLION) 157.
TABLE 109 IMMUNOASSAY MARKET, BY TECHNOLOGY, 2024–2031 (USD MILLION) 159.
TABLE 110 KEY ELISA TECHNOLOGIES AVAILABLE IN MARKET 160.
TABLE 111 IMMUNOASSAY MARKET FOR ELISA, BY REGION, 2024–2031 (USD MILLION) 161.
TABLE 112 NORTH AMERICA: IMMUNOASSAY MARKET FOR ELISA, BY COUNTRY,.
2024–2031 (USD MILLION) 161.
TABLE 113 EUROPE: IMMUNOASSAY MARKET FOR ELISA, BY COUNTRY,.
2024–2031 (USD MILLION) 162.
TABLE 114 ASIA PACIFIC: IMMUNOASSAY MARKET FOR ELISA, BY COUNTRY,.
2024–2031 (USD MILLION) 162.
TABLE 115 LATIN AMERICA: IMMUNOASSAY MARKET FOR ELISA, BY COUNTRY,.
2024–2031 (USD MILLION) 163.
TABLE 116 IMMUNOASSAY MARKET FOR CLIA, BY REGION, 2024–2031 (USD MILLION) 164.
TABLE 117 NORTH AMERICA: IMMUNOASSAY MARKET FOR CLIA, BY COUNTRY,.
2024–2031 (USD MILLION) 164.
TABLE 118 EUROPE: IMMUNOASSAY MARKET FOR CLIA, BY COUNTRY,.
2024–2031 (USD MILLION) 165.
TABLE 119 ASIA PACIFIC: IMMUNOASSAY MARKET FOR CLIA, BY COUNTRY,.
2024–2031 (USD MILLION) 165.
TABLE 120 LATIN AMERICA: IMMUNOASSAY MARKET FOR CLIA, BY COUNTRY,.
2024–2031 (USD MILLION) 166.
TABLE 121 IMMUNOASSAY MARKET FOR IFA, BY REGION, 2024–2031 (USD MILLION) 167.
TABLE 122 NORTH AMERICA: IMMUNOASSAY MARKET FOR IFA, BY COUNTRY,.
2024–2031 (USD MILLION) 167.
TABLE 123 EUROPE: IMMUNOASSAY MARKET FOR IFA, BY COUNTRY,.
2024–2031 (USD MILLION) 168.
TABLE 124 ASIA PACIFIC: IMMUNOASSAY MARKET FOR IFA, BY COUNTRY,.
2024–2031 (USD MILLION) 168.
TABLE 125 LATIN AMERICA: IMMUNOASSAY MARKET FOR IFA, BY COUNTRY,.
2024–2031 (USD MILLION) 169.
TABLE 126 KEY RAPID TESTS AVAILABLE IN MARKET 169.
TABLE 127 IMMUNOASSAY MARKET FOR RAPID TESTS, BY REGION,.
2024–2031 (USD MILLION) 170.
TABLE 128 NORTH AMERICA: IMMUNOASSAY MARKET FOR RAPID TESTS, BY COUNTRY, 2024–2031 (USD MILLION) 170.
TABLE 129 EUROPE: IMMUNOASSAY MARKET FOR RAPID TESTS, BY COUNTRY,.
2024–2031 (USD MILLION) 171.
TABLE 130 ASIA PACIFIC: IMMUNOASSAY MARKET FOR RAPID TESTS, BY COUNTRY,.
2024–2031 (USD MILLION) 171.
TABLE 131 LATIN AMERICA: IMMUNOASSAY MARKET FOR RAPID TESTS, BY COUNTRY,.
2024–2031 (USD MILLION) 172.
TABLE 132 KEY WESTERN BLOTTING SYSTEMS AVAILABLE IN MARKET 172.
TABLE 133 IMMUNOASSAY MARKET FOR WESTERN BLOTTING, BY REGION,.
2024–2031 (USD MILLION) 173.
TABLE 134 NORTH AMERICA: IMMUNOASSAY MARKET FOR WESTERN BLOTTING,.
BY COUNTRY, 2024–2031 (USD MILLION) 173.
TABLE 135 EUROPE: IMMUNOASSAY MARKET FOR WESTERN BLOTTING, BY COUNTRY,.
2024–2031 (USD MILLION) 174.
TABLE 136 ASIA PACIFIC: IMMUNOASSAY MARKET FOR WESTERN BLOTTING, BY COUNTRY, 2024–2031 (USD MILLION) 174.
TABLE 137 LATIN AMERICA: IMMUNOASSAY MARKET FOR WESTERN BLOTTING, BY COUNTRY, 2024–2031 (USD MILLION) 175.
TABLE 138 IMMUNOASSAY MARKET FOR OTHER TECHNOLOGIES, BY REGION,.
2024–2031 (USD MILLION) 176.
TABLE 139 NORTH AMERICA: IMMUNOASSAY MARKET FOR OTHER TECHNOLOGIES,.
BY COUNTRY, 2024–2031 (USD MILLION) 176.
TABLE 140 EUROPE: IMMUNOASSAY MARKET FOR OTHER TECHNOLOGIES, BY COUNTRY, 2024–2031 (USD MILLION) 177.
TABLE 141 ASIA PACIFIC: IMMUNOASSAY MARKET FOR OTHER TECHNOLOGIES,.
BY COUNTRY, 2024–2031 (USD MILLION) 177.
TABLE 142 LATIN AMERICA: IMMUNOASSAY MARKET FOR OTHER TECHNOLOGIES,.
BY COUNTRY, 2024–2031 (USD MILLION) 178.
TABLE 143 IMMUNOASSAY MARKET, BY SPECIMEN, 2024–2031 (USD MILLION) 180.
TABLE 144 IMMUNOASSAY MARKET FOR BLOOD SPECIMENS, BY REGION,.
2024–2031 (USD MILLION) 181.
TABLE 145 NORTH AMERICA: IMMUNOASSAY MARKET FOR BLOOD SPECIMENS, BY COUNTRY, 2024–2031 (USD MILLION) 182.
TABLE 146 EUROPE: IMMUNOASSAY MARKET FOR BLOOD SPECIMENS, BY COUNTRY,.
2024–2031 (USD MILLION) 182.
TABLE 147 ASIA PACIFIC: IMMUNOASSAY MARKET FOR BLOOD SPECIMENS, BY COUNTRY, 2024–2031 (USD MILLION) 183.
TABLE 148 LATIN AMERICA: IMMUNOASSAY MARKET FOR BLOOD SPECIMENS, BY COUNTRY, 2024–2031 (USD MILLION) 183.
TABLE 149 IMMUNOASSAY MARKET FOR SALIVA SPECIMENS, BY REGION,.
2024–2031 (USD MILLION) 184.
TABLE 150 NORTH AMERICA: IMMUNOASSAY MARKET FOR SALIVA SPECIMENS, BY COUNTRY, 2024–2031 (USD MILLION) 185.
TABLE 151 EUROPE: IMMUNOASSAY MARKET FOR SALIVA SPECIMENS, BY COUNTRY,.
2024–2031 (USD MILLION) 185.
TABLE 152 ASIA PACIFIC: IMMUNOASSAY MARKET FOR SALIVA SPECIMENS, BY COUNTRY, 2024–2031 (USD MILLION) 186.
TABLE 153 LATIN AMERICA: IMMUNOASSAY MARKET FOR SALIVA SPECIMENS, BY COUNTRY, 2024–2031 (USD MILLION) 186.
TABLE 154 IMMUNOASSAY MARKET FOR URINE SPECIMENS, BY REGION,.
2024–2031 (USD MILLION) 187.
TABLE 155 NORTH AMERICA: IMMUNOASSAY MARKET FOR URINE SPECIMENS, BY COUNTRY, 2024–2031 (USD MILLION) 188.
TABLE 156 EUROPE: IMMUNOASSAY MARKET FOR URINE SPECIMENS, BY COUNTRY,.
2024–2031 (USD MILLION) 188.
TABLE 157 ASIA PACIFIC: IMMUNOASSAY MARKET FOR URINE SPECIMENS, BY COUNTRY, 2024–2031 (USD MILLION) 189.
TABLE 158 LATIN AMERICA: IMMUNOASSAY MARKET FOR URINE SPECIMENS, BY COUNTRY, 2024–2031 (USD MILLION) 189.
TABLE 159 IMMUNOASSAY MARKET FOR OTHER SPECIMENS, BY REGION,.
2024–2031 (USD MILLION) 190.
TABLE 160 NORTH AMERICA: IMMUNOASSAY MARKET FOR OTHER SPECIMENS, BY COUNTRY, 2024–2031 (USD MILLION) 191.
TABLE 161 EUROPE: IMMUNOASSAY MARKET FOR OTHER SPECIMENS, BY COUNTRY,.
2024–2031 (USD MILLION) 191.
TABLE 162 ASIA PACIFIC: IMMUNOASSAY MARKET FOR OTHER SPECIMENS, BY COUNTRY, 2024–2031 (USD MILLION) 192.
TABLE 163 LATIN AMERICA: IMMUNOASSAY MARKET FOR OTHER SPECIMENS, BY COUNTRY, 2024–2031 (USD MILLION) 192.
TABLE 164 IMMUNOASSAY MARKET, BY APPLICATION, 2024–2031 (USD MILLION) 194.
TABLE 165 IMMUNOASSAY MARKET FOR INFECTIOUS DISEASES, BY REGION, 2024–2031 (USD MILLION) 195.
TABLE 166 NORTH AMERICA: IMMUNOASSAY MARKET FOR INFECTIOUS DISEASES,.
BY COUNTRY, 2024–2031 (USD MILLION) 196.
TABLE 167 EUROPE: IMMUNOASSAY MARKET FOR INFECTIOUS DISEASES, BY COUNTRY, 2024–2031 (USD MILLION) 196.
TABLE 168 ASIA PACIFIC: IMMUNOASSAY MARKET FOR INFECTIOUS DISEASES, BY COUNTRY, 2024–2031 (USD MILLION) 197.
TABLE 169 LATIN AMERICA: IMMUNOASSAY MARKET FOR INFECTIOUS DISEASES,.
BY COUNTRY, 2024–2031 (USD MILLION) 197.
TABLE 170 IMMUNOASSAY MARKET FOR ENDOCRINOLOGY, BY REGION,.
2024–2031 (USD MILLION) 198.
TABLE 171 NORTH AMERICA: IMMUNOASSAY MARKET FOR ENDOCRINOLOGY,.
BY COUNTRY, 2024–2031 (USD MILLION) 199.
TABLE 172 EUROPE: IMMUNOASSAY MARKET FOR ENDOCRINOLOGY, BY COUNTRY,.
2024–2031 (USD MILLION) 199.
TABLE 173 ASIA PACIFIC: IMMUNOASSAY MARKET FOR ENDOCRINOLOGY, BY COUNTRY, 2024–2031 (USD MILLION) 200.
TABLE 174 LATIN AMERICA: IMMUNOASSAY MARKET FOR ENDOCRINOLOGY, BY COUNTRY, 2024–2031 (USD MILLION) 200.
TABLE 175 KEY PRODUCTS AVAILABLE FOR CARDIOLOGY APPLICATIONS 202.
TABLE 176 IMMUNOASSAY MARKET FOR CARDIOLOGY, BY REGION,.
2024–2031 (USD MILLION) 202.
TABLE 177 NORTH AMERICA: IMMUNOASSAY MARKET FOR CARDIOLOGY, BY COUNTRY, 2024–2031 (USD MILLION) 203.
TABLE 178 EUROPE: IMMUNOASSAY MARKET FOR CARDIOLOGY, BY COUNTRY,.
2024–2031 (USD MILLION) 203.
TABLE 179 ASIA PACIFIC: IMMUNOASSAY MARKET FOR CARDIOLOGY, BY COUNTRY,.
2024–2031 (USD MILLION) 204.
TABLE 180 LATIN AMERICA: IMMUNOASSAY MARKET FOR CARDIOLOGY, BY COUNTRY,.
2024–2031 (USD MILLION) 204.
TABLE 181 IMMUNOASSAY MARKET FOR AUTOIMMUNE DISORDERS, BY REGION,.
2024–2031 (USD MILLION) 205.
TABLE 182 NORTH AMERICA: IMMUNOASSAY MARKET FOR AUTOIMMUNE DISORDERS,.
BY COUNTRY, 2024–2031 (USD MILLION) 206.
TABLE 183 EUROPE: IMMUNOASSAY MARKET FOR AUTOIMMUNE DISORDERS, BY COUNTRY, 2024–2031 (USD MILLION) 206.
TABLE 184 ASIA PACIFIC: IMMUNOASSAY MARKET FOR AUTOIMMUNE DISORDERS,.
BY COUNTRY, 2024–2031 (USD MILLION) 207.
TABLE 185 LATIN AMERICA: IMMUNOASSAY MARKET FOR AUTOIMMUNE DISORDERS,.
BY COUNTRY, 2024–2031 (USD MILLION) 207.
TABLE 186 IMMUNOASSAY MARKET FOR ALLERGY DIAGNOSTICS, BY REGION,.
2024–2031 (USD MILLION) 208.
TABLE 187 NORTH AMERICA: IMMUNOASSAY MARKET FOR ALLERGY DIAGNOSTICS,.
BY COUNTRY, 2024–2031 (USD MILLION) 209.
TABLE 188 EUROPE: IMMUNOASSAY MARKET FOR ALLERGY DIAGNOSTICS, BY COUNTRY, 2024–2031 (USD MILLION) 209.
TABLE 189 ASIA PACIFIC: IMMUNOASSAY MARKET FOR ALLERGY DIAGNOSTICS,.
BY COUNTRY, 2024–2031 (USD MILLION) 210.
TABLE 190 LATIN AMERICA: IMMUNOASSAY MARKET FOR ALLERGY DIAGNOSTICS,.
BY COUNTRY, 2024–2031 (USD MILLION) 210.
TABLE 191 IMMUNOASSAY MARKET FOR ONCOLOGY, BY REGION, 2024–2031 (USD MILLION) 212.
TABLE 192 NORTH AMERICA: IMMUNOASSAY MARKET FOR ONCOLOGY, BY COUNTRY,.
2024–2031 (USD MILLION) 212.
TABLE 193 EUROPE: IMMUNOASSAY MARKET FOR ONCOLOGY, BY COUNTRY,.
2024–2031 (USD MILLION) 213.
TABLE 194 ASIA PACIFIC: IMMUNOASSAY MARKET FOR ONCOLOGY, BY COUNTRY,.
2024–2031 (USD MILLION) 213.
TABLE 195 LATIN AMERICA: IMMUNOASSAY MARKET FOR ONCOLOGY, BY COUNTRY,.
2024–2031 (USD MILLION) 214.
TABLE 196 KEY PRODUCTS AVAILABLE FOR BONE & MINERAL DISORDERS 215.
TABLE 197 IMMUNOASSAY MARKET FOR BONE & MINERAL DISORDERS, BY REGION,.
2024–2031 (USD MILLION) 215.
TABLE 198 NORTH AMERICA: IMMUNOASSAY MARKET FOR BONE & MINERAL DISORDERS,.
BY COUNTRY, 2024–2031 (USD MILLION) 216.
TABLE 199 EUROPE: IMMUNOASSAY MARKET FOR BONE & MINERAL DISORDERS,.
BY COUNTRY, 2024–2031 (USD MILLION) 216.
TABLE 200 ASIA PACIFIC: IMMUNOASSAY MARKET FOR BONE & MINERAL DISORDERS,.
BY COUNTRY, 2024–2031 (USD MILLION) 217.
TABLE 201 LATIN AMERICA: IMMUNOASSAY MARKET FOR BONE & MINERAL DISORDERS,.
BY COUNTRY, 2024–2031 (USD MILLION) 217.
TABLE 202 KEY PRODUCTS AVAILABLE FOR DRUG MONITORING & TESTING 218.
TABLE 203 KEY IMMUNOASSAY PRODUCTS AVAILABLE FOR DRUG MONITORING & TESTING 219.
TABLE 204 IMMUNOASSAY MARKET FOR DRUG MONITORING & TESTING, BY REGION,.
2024–2031 (USD MILLION) 219.
TABLE 205 NORTH AMERICA: IMMUNOASSAY MARKET FOR DRUG MONITORING & TESTING, BY COUNTRY, 2024–2031 (USD MILLION) 219.
TABLE 206 EUROPE: IMMUNOASSAY MARKET FOR DRUG MONITORING & TESTING,.
BY COUNTRY, 2024–2031 (USD MILLION) 220.
TABLE 207 ASIA PACIFIC: IMMUNOASSAY MARKET FOR DRUG MONITORING & TESTING,.
BY COUNTRY, 2024–2031 (USD MILLION) 220.
TABLE 208 LATIN AMERICA: IMMUNOASSAY MARKET FOR DRUG MONITORING & TESTING,.
BY COUNTRY, 2024–2031 (USD MILLION) 221.
TABLE 209 IMMUNOASSAY MARKET FOR BLOOD SCREENING, BY REGION,.
2024–2031 (USD MILLION) 222.
TABLE 210 NORTH AMERICA: IMMUNOASSAY MARKET FOR BLOOD SCREENING, BY COUNTRY, 2024–2031 (USD MILLION) 222.
TABLE 211 EUROPE: IMMUNOASSAY MARKET FOR BLOOD SCREENING, BY COUNTRY,.
2024–2031 (USD MILLION) 223.
TABLE 212 ASIA PACIFIC: IMMUNOASSAY MARKET FOR BLOOD SCREENING, BY COUNTRY, 2024–2031 (USD MILLION) 223.
TABLE 213 LATIN AMERICA: IMMUNOASSAY MARKET FOR BLOOD SCREENING, BY COUNTRY, 2024–2031 (USD MILLION) 224.
TABLE 214 KEY PRODUCTS AVAILABLE FOR NEWBORN SCREENING 224.
TABLE 215 IMMUNOASSAY MARKET FOR NEWBORN SCREENING, BY REGION,.
2024–2031 (USD MILLION) 225.
TABLE 216 NORTH AMERICA: IMMUNOASSAY MARKET FOR NEWBORN SCREENING,.
BY COUNTRY, 2024–2031 (USD MILLION) 225.
TABLE 217 EUROPE: IMMUNOASSAY MARKET FOR NEWBORN SCREENING, BY COUNTRY, 2024–2031 (USD MILLION) 226.
TABLE 218 ASIA PACIFIC: IMMUNOASSAY MARKET FOR NEWBORN SCREENING, BY COUNTRY, 2024–2031 (USD MILLION) 226.
TABLE 219 LATIN AMERICA: IMMUNOASSAY MARKET FOR NEWBORN SCREENING,.
BY COUNTRY, 2024–2031 (USD MILLION) 227.
TABLE 220 IMMUNOASSAY MARKET FOR OTHER APPLICATIONS, BY REGION,.
2024–2031 (USD MILLION) 228.
TABLE 221 NORTH AMERICA: IMMUNOASSAY MARKET FOR OTHER APPLICATIONS,.
BY COUNTRY, 2024–2031 (USD MILLION) 228.
TABLE 222 EUROPE: IMMUNOASSAY MARKET FOR OTHER APPLICATIONS, BY COUNTRY, 2024–2031 (USD MILLION) 229.
TABLE 223 ASIA PACIFIC: IMMUNOASSAY MARKET FOR OTHER APPLICATIONS, BY COUNTRY, 2024–2031 (USD MILLION) 229.
TABLE 224 LATIN AMERICA: IMMUNOASSAY MARKET FOR OTHER APPLICATIONS,.
BY COUNTRY, 2024–2031 (USD MILLION) 230.
TABLE 225 IMMUNOASSAY MARKET, BY END USER, 2024–2031 (USD MILLION) 232.
TABLE 226 IMMUNOASSAY MARKET FOR HOSPITALS & CLINICS, BY REGION,.
2024–2031 (USD MILLION) 233.
TABLE 227 NORTH AMERICA: IMMUNOASSAY MARKET FOR HOSPITALS & CLINICS,.
BY COUNTRY, 2024–2031 (USD MILLION) 234.
TABLE 228 EUROPE: IMMUNOASSAY MARKET FOR HOSPITALS & CLINICS, BY COUNTRY, 2024–2031 (USD MILLION) 234.
TABLE 229 ASIA PACIFIC: IMMUNOASSAY MARKET FOR HOSPITALS & CLINICS,.
BY COUNTRY, 2024–2031 (USD MILLION) 235.
TABLE 230 LATIN AMERICA: IMMUNOASSAY MARKET FOR HOSPITALS & CLINICS,.
BY COUNTRY, 2024–2031 (USD MILLION) 235.
TABLE 231 IMMUNOASSAY MARKET FOR CLINICAL LABORATORIES, BY REGION,.
2024–2031 (USD MILLION) 237.
TABLE 232 NORTH AMERICA: IMMUNOASSAY MARKET FOR CLINICAL LABORATORIES,.
BY COUNTRY, 2024–2031 (USD MILLION) 237.
TABLE 233 EUROPE: IMMUNOASSAY MARKET FOR CLINICAL LABORATORIES, BY COUNTRY, 2024–2031 (USD MILLION) 238.
TABLE 234 ASIA PACIFIC: IMMUNOASSAY MARKET FOR CLINICAL LABORATORIES,.
BY COUNTRY, 2024–2031 (USD MILLION) 238.
TABLE 235 LATIN AMERICA: IMMUNOASSAY MARKET FOR CLINICAL LABORATORIES,.
BY COUNTRY, 2024–2031 (USD MILLION) 239.
TABLE 236 IMMUNOASSAY MARKET FOR HOME CARE SETTINGS, BY REGION,.
2024–2031 (USD MILLION) 240.
TABLE 237 NORTH AMERICA: IMMUNOASSAY MARKET FOR HOME CARE SETTINGS,.
BY COUNTRY, 2024–2031 (USD MILLION) 240.
TABLE 238 EUROPE: IMMUNOASSAY MARKET FOR HOME CARE SETTINGS, BY COUNTRY, 2024–2031 (USD MILLION) 241.
TABLE 239 ASIA PACIFIC: IMMUNOASSAY MARKET FOR HOME CARE SETTINGS, BY COUNTRY, 2024–2031 (USD MILLION) 241.
TABLE 240 LATIN AMERICA: IMMUNOASSAY MARKET FOR HOME CARE SETTINGS,.
BY COUNTRY, 2024–2031 (USD MILLION) 242.
TABLE 241 IMMUNOASSAY MARKET FOR BLOOD BANKS, BY REGION,.
2024–2031 (USD MILLION) 243.
TABLE 242 NORTH AMERICA: IMMUNOASSAY MARKET FOR BLOOD BANKS, BY COUNTRY, 2024–2031 (USD MILLION) 243.
TABLE 243 EUROPE: IMMUNOASSAY MARKET FOR BLOOD BANKS, BY COUNTRY,.
2024–2031 (USD MILLION) 244.
TABLE 244 ASIA PACIFIC: IMMUNOASSAY MARKET FOR BLOOD BANKS, BY COUNTRY,.
2024–2031 (USD MILLION) 244.
TABLE 245 LATIN AMERICA: IMMUNOASSAY MARKET FOR BLOOD BANKS, BY COUNTRY, 2024–2031 (USD MILLION) 245.
TABLE 246 IMMUNOASSAY MARKET, BY REGION, 2024–2031 (USD MILLION) 247.
TABLE 247 NORTH AMERICA: IMMUNOASSAY MARKET, BY COUNTRY,.
2024–2031 (USD MILLION) 249.
TABLE 248 NORTH AMERICA: IMMUNOASSAY MARKET, BY PRODUCT,.
2024–2031 (USD MILLION) 249.
TABLE 249 NORTH AMERICA: IMMUNOASSAY REAGENTS & KITS MARKET, BY TYPE,.
2024–2031 (USD MILLION) 250.
TABLE 250 NORTH AMERICA: IMMUNOASSAY ANALYZERS MARKET, BY TYPE,.
2024–2031 (USD MILLION) 250.
TABLE 251 NORTH AMERICA: IMMUNOASSAY ANALYZERS MARKET, BY PURCHASE MODE, 2024–2031 (USD MILLION) 251.
TABLE 252 NORTH AMERICA: IMMUNOASSAY MARKET, BY TECHNOLOGY,.
2024–2031 (USD MILLION) 251.
TABLE 253 NORTH AMERICA: IMMUNOASSAY MARKET, BY SPECIMEN,.
2024–2031 (USD MILLION) 252.
TABLE 254 NORTH AMERICA: IMMUNOASSAY MARKET, BY APPLICATION,.
2024–2031 (USD MILLION) 252.
TABLE 255 NORTH AMERICA: IMMUNOASSAY MARKET, BY END USER,.
2024–2031 (USD MILLION) 253.
TABLE 256 US: NUMBER OF IN VITRO DIAGNOSTIC TESTS CONDUCTED,.
2022–2031 (BILLION UNITS) 254.
TABLE 257 US: IMMUNOASSAY MARKET, BY PRODUCT, 2024–2031 (USD MILLION) 255.
TABLE 258 US: IMMUNOASSAY REAGENTS & KITS MARKET, BY TYPE,.
2024–2031 (USD MILLION) 255.
TABLE 259 US: IMMUNOASSAY ANALYZERS MARKET, BY TYPE, 2024–2031 (USD MILLION) 256.
TABLE 260 US: IMMUNOASSAY ANALYZERS MARKET, BY PURCHASE MODE,.
2024–2031 (USD MILLION) 256.
TABLE 261 US: IMMUNOASSAY MARKET, BY TECHNOLOGY, 2024–2031 (USD MILLION) 257.
TABLE 262 US: IMMUNOASSAY MARKET, BY SPECIMEN, 2024–2031 (USD MILLION) 257.
TABLE 263 US: IMMUNOASSAY MARKET, BY APPLICATION, 2024–2031 (USD MILLION) 258.
TABLE 264 US: IMMUNOASSAY MARKET, BY END USER, 2024–2031 (USD MILLION) 258.
TABLE 265 CANADA: ESTIMATED PREVALENCE OF DIABETES, 2025 VS. 2034 259.
TABLE 266 CANADA: IMMUNOASSAY MARKET, BY PRODUCT, 2024–2031 (USD MILLION) 260.
TABLE 267 CANADA: IMMUNOASSAY REAGENTS & KITS MARKET, BY TYPE,.
2024–2031 (USD MILLION) 260.
TABLE 268 CANADA: IMMUNOASSAY ANALYZERS MARKET, BY TYPE,.
2024–2031 (USD MILLION) 261.
TABLE 269 CANADA: IMMUNOASSAY ANALYZERS MARKET, BY PURCHASE MODE,.
2024–2031 (USD MILLION) 261.
TABLE 270 CANADA: IMMUNOASSAY MARKET, BY TECHNOLOGY, 2024–2031 (USD MILLION) 262.
TABLE 271 CANADA: IMMUNOASSAY MARKET, BY SPECIMEN, 2024–2031 (USD MILLION) 262.
TABLE 272 CANADA: IMMUNOASSAY MARKET, BY APPLICATION, 2024–2031 (USD MILLION) 263.
TABLE 273 CANADA: IMMUNOASSAY MARKET, BY END USER, 2024–2031 (USD MILLION) 263.
TABLE 274 EUROPE: IMMUNOASSAY MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 264.
TABLE 275 EUROPE: IMMUNOASSAY MARKET, BY PRODUCT, 2024–2031 (USD MILLION) 265.
TABLE 276 EUROPE: IMMUNOASSAY REAGENTS & KITS MARKET, BY TYPE,.
2024–2031 (USD MILLION) 265.
TABLE 277 EUROPE: IMMUNOASSAY ANALYZERS MARKET, BY TYPE,.
2024–2031 (USD MILLION) 266.
TABLE 278 EUROPE: IMMUNOASSAY ANALYZERS MARKET, BY PURCHASE MODE,.
2024–2031 (USD MILLION) 266.
TABLE 279 EUROPE: IMMUNOASSAY MARKET, BY TECHNOLOGY, 2024–2031 (USD MILLION) 267.
TABLE 280 EUROPE: IMMUNOASSAY MARKET, BY SPECIMEN, 2024–2031 (USD MILLION) 267.
TABLE 281 EUROPE: IMMUNOASSAY MARKET, BY APPLICATION, 2024–2031 (USD MILLION) 268.
TABLE 282 EUROPE: IMMUNOASSAY MARKET, BY END USER, 2024–2031 (USD MILLION) 268.
TABLE 283 GERMANY: IMMUNOASSAY MARKET, BY PRODUCT, 2024–2031 (USD MILLION) 269.
TABLE 284 GERMANY: IMMUNOASSAY REAGENTS & KITS MARKET, BY TYPE,.
2024–2031 (USD MILLION) 270.
TABLE 285 GERMANY: IMMUNOASSAY ANALYZERS MARKET, BY TYPE,.
2024–2031 (USD MILLION) 270.
TABLE 286 GERMANY: IMMUNOASSAY ANALYZERS MARKET, BY PURCHASE MODE,.
2024–2031 (USD MILLION) 271.
TABLE 287 GERMANY: IMMUNOASSAY MARKET, BY TECHNOLOGY,.
2024–2031 (USD MILLION) 271.
TABLE 288 GERMANY: IMMUNOASSAY MARKET, BY SPECIMEN, 2024–2031 (USD MILLION) 272.
TABLE 289 GERMANY: IMMUNOASSAY MARKET, BY APPLICATION, 2024–2031 (USD MILLION) 272.
TABLE 290 GERMANY: IMMUNOASSAY MARKET, BY END USER, 2024–2031 (USD MILLION) 273.
TABLE 291 ITALY: IMMUNOASSAY MARKET, BY PRODUCT, 2024–2031 (USD MILLION) 274.
TABLE 292 ITALY: IMMUNOASSAY REAGENTS & KITS MARKET, BY TYPE,.
2024–2031 (USD MILLION) 274.
TABLE 293 ITALY: IMMUNOASSAY ANALYZERS MARKET, BY TYPE, 2024–2031 (USD MILLION) 275.
TABLE 294 ITALY: IMMUNOASSAY ANALYZERS MARKET, BY PURCHASE MODE,.
2024–2031 (USD MILLION) 275.
TABLE 295 ITALY: IMMUNOASSAY MARKET, BY TECHNOLOGY, 2024–2031 (USD MILLION) 276.
TABLE 296 ITALY: IMMUNOASSAY MARKET, BY SPECIMEN, 2024–2031 (USD MILLION) 276.
TABLE 297 ITALY: IMMUNOASSAY MARKET, BY APPLICATION, 2024–2031 (USD MILLION) 277.
TABLE 298 ITALY: IMMUNOASSAY MARKET, BY END USER, 2024–2031 (USD MILLION) 277.
TABLE 299 FRANCE: IMMUNOASSAY MARKET, BY PRODUCT, 2024–2031 (USD MILLION) 278.
TABLE 300 FRANCE: IMMUNOASSAY REAGENTS & KITS MARKET, BY TYPE,.
2024–2031 (USD MILLION) 279.
TABLE 301 FRANCE: IMMUNOASSAY ANALYZERS MARKET, BY TYPE,.
2024–2031 (USD MILLION) 279.
TABLE 302 FRANCE: IMMUNOASSAY ANALYZERS MARKET, BY PURCHASE MODE,.
2024–2031 (USD MILLION) 280.
TABLE 303 FRANCE: IMMUNOASSAY MARKET, BY TECHNOLOGY, 2024–2031 (USD MILLION) 280.
TABLE 304 FRANCE: IMMUNOASSAY MARKET, BY SPECIMEN, 2024–2031 (USD MILLION) 281.
TABLE 305 FRANCE: IMMUNOASSAY MARKET, BY APPLICATION, 2024–2031 (USD MILLION) 281.
TABLE 306 FRANCE: IMMUNOASSAY MARKET, BY END USER, 2024–2031 (USD MILLION) 282.
TABLE 307 UK: IMMUNOASSAY MARKET, BY PRODUCT, 2024–2031 (USD MILLION) 283.
TABLE 308 UK: IMMUNOASSAY REAGENTS & KITS MARKET, BY TYPE,.
2024–2031 (USD MILLION) 284.

 

ページTOPに戻る

ご注文は、お電話またはWEBから承ります。お見積もりの作成もお気軽にご相談ください。

webからのご注文・お問合せはこちらのフォームから承ります

本レポートと同じKEY WORD(immunoassay)の最新刊レポート


よくあるご質問


MarketsandMarkets社はどのような調査会社ですか?


マーケッツアンドマーケッツ(MarketsandMarkets)は通信、半導体、医療機器、エネルギーなど、幅広い市場に関する調査レポートを出版しています。また広範な市場を対象としたカスタム調査も行って... もっと見る


調査レポートの納品までの日数はどの程度ですか?


在庫のあるものは速納となりますが、平均的には 3-4日と見て下さい。
但し、一部の調査レポートでは、発注を受けた段階で内容更新をして納品をする場合もあります。
発注をする前のお問合せをお願いします。


注文の手続きはどのようになっていますか?


1)お客様からの御問い合わせをいただきます。
2)見積書やサンプルの提示をいたします。
3)お客様指定、もしくは弊社の発注書をメール添付にて発送してください。
4)データリソース社からレポート発行元の調査会社へ納品手配します。
5) 調査会社からお客様へ納品されます。最近は、pdfにてのメール納品が大半です。


お支払方法の方法はどのようになっていますか?


納品と同時にデータリソース社よりお客様へ請求書(必要に応じて納品書も)を発送いたします。
お客様よりデータリソース社へ(通常は円払い)の御振り込みをお願いします。
請求書は、納品日の日付で発行しますので、翌月最終営業日までの当社指定口座への振込みをお願いします。振込み手数料は御社負担にてお願いします。
お客様の御支払い条件が60日以上の場合は御相談ください。
尚、初めてのお取引先や個人の場合、前払いをお願いすることもあります。ご了承のほど、お願いします。


データリソース社はどのような会社ですか?


当社は、世界各国の主要調査会社・レポート出版社と提携し、世界各国の市場調査レポートや技術動向レポートなどを日本国内の企業・公官庁及び教育研究機関に提供しております。
世界各国の「市場・技術・法規制などの」実情を調査・収集される時には、データリソース社にご相談ください。
お客様の御要望にあったデータや情報を抽出する為のレポート紹介や調査のアドバイスも致します。


詳細検索

このレポートへのお問合せ

03-3582-2531

電話お問合せもお気軽に

 

 

2026/11/19 10:27

160.48 円

176.53 円

213.76 円

ページTOPに戻る